var title_f29_22_30048="HCM treatment algorithm";
var content_f29_22_30048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F86793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F86793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    HCM treatment algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 691px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; DM: diabetes mellitus; EF: ejection fraction; GL: guidelines; HCM: hypertrophic cardiomyopathy; HTN: hypertension; LV: left ventricular.",
"     <br/>",
"     * Class I.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Class IIa.",
"     <br/>",
"     &Delta; Class IIb.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2761. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30048=[""].join("\n");
var outline_f29_22_30048=null;
var title_f29_22_30049="Primary tracheal tumor CT";
var content_f29_22_30049=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary tracheal tumor from a minor salivary gland in 49-year-old male",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of patient who was treated with primary resection and adjuvant radiotherapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James R Jett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30049=[""].join("\n");
var outline_f29_22_30049=null;
var title_f29_22_30050="Hydropneumothorax in rheumatoid arthritis";
var content_f29_22_30050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F88944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F88944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Hydropneumothorax with irregular pleural thickening in a patient with rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 191px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph (A) shows an&nbsp;atypical loculated right pneumothorax with two separate collections of pleural gas in a patient with known rheumatoid arthritis. CT thorax image (B) shows chronic right hydropneumothorax with gas-liquid level due to bronchopleural fistula and irregular visceral and parietal pleural thickening.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30050=[""].join("\n");
var outline_f29_22_30050=null;
var title_f29_22_30051="J wave";
var content_f29_22_30051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    J or Osborn wave",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ECG change with hypothermia, including presence of J wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hickey R, De Caen A. Warming Procedures. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30051=[""].join("\n");
var outline_f29_22_30051=null;
var title_f29_22_30052="Patient information: Medicines for asthma (The Basics)";
var content_f29_22_30052=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16117\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/52/837\">",
"         Asthma and its treatment",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/35/37439\">",
"          Metered dose inhaler",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?4/11/4275\">",
"         Patient information: Asthma in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/58/17315\">",
"         Patient information: Asthma in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/47/9970\">",
"         Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/34/41506\">",
"         Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/43/30386\">",
"         Patient information: Inhalers (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/25/29075\">",
"         Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/3/44083\">",
"         Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/63/39925\">",
"         Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/60/18374\">",
"         Patient information: Asthma treatment in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Medicines for asthma (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/medicines-for-asthma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H24479256\">",
"      <span class=\"h1\">",
"       What do asthma medicines do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you or your child has asthma, the medicines the doctor prescribes can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Reduce asthma symptoms &ndash; This can make daily activities easier.",
"       </li>",
"       <li>",
"        Help prevent asthma attacks or stop them if they happen.",
"       </li>",
"       <li>",
"        Help prevent lung damage &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24479271\">",
"      <span class=\"h1\">",
"       Which medicines might I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can use different medicines to treat asthma. These include inhalers, liquids, and pills. You might take 1 or more depending on how often you have symptoms and how serious they are. The medicine and amount you take might change over time.",
"     </p>",
"     <p>",
"      There are 2 main types of asthma medicines:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Quick-relief medicines",
"        </strong>",
"        can reduce symptoms in 5 to 15 minutes. People use these medicines to treat asthma attacks or asthma flare-ups.",
"       </li>",
"       <li>",
"        <strong>",
"         Long-term controller medicines",
"        </strong>",
"        help keep asthma symptoms from happening. People take these 1 or 2 times a day every day, even if they have no symptoms. When these medicines are working well, you should need quick-relief medicines less than 2 times a week.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The medicines listed below are the most common types of asthma medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24479286\">",
"      <span class=\"h1\">",
"       Short-acting beta agonists",
"      </span>",
"      &nbsp;&mdash;&nbsp;Short-acting beta agonists (called &ldquo;SABAs&rdquo; or &ldquo;short-acting bronchodilators&rdquo;) are quick-relief medicines. They relax the muscles around the airways (",
"      <a class=\"graphic graphic_figure graphicRef65956 \" href=\"UTD.htm?0/52/837\">",
"       figure 1",
"      </a>",
"      ). They usually come in a metered dose inhaler (",
"      <a class=\"graphic graphic_picture graphicRef61575 \" href=\"UTD.htm?36/35/37439\">",
"       picture 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      If you have asthma symptoms when you exercise, it can help to use a SABA 15 minutes before exercise. SABAs can also help stop an asthma attack. Some people feel shaky after taking a SABA. If this happens, your doctor or nurse might tell you to use just 1 puff next time. Or he or she might give you a different medicine. &nbsp;",
"     </p>",
"     <p>",
"      Some examples of SABAs are",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?39/50/40741?source=see_link\">",
"       albuterol",
"      </a>",
"      (sample brand names: ProAir&reg; HFA, Proventil&reg; HFA, Ventolin&reg; HFA) and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?22/7/22645?source=see_link\">",
"       levalbuterol",
"      </a>",
"      (brand name: Xopenex HFA&trade;).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24479301\">",
"      <span class=\"h1\">",
"       Inhaled steroids",
"      </span>",
"      &nbsp;&mdash;&nbsp;Inhaled steroids are long-term controller medicines that reduce inflammation in the airways. They help prevent symptoms and asthma attacks in the future. They also help keep asthma from damaging the lungs.",
"     </p>",
"     <p>",
"      Inhaled steroids come in different kinds of inhalers. Your doctor or nurse will show you how to use the inhaler. Each inhaler has its own directions.",
"     </p>",
"     <p>",
"      The steroids used to treat asthma are different from the ones athletes take to build muscle. It is rare for these medicines to cause side effects. The doctor will give the lowest dose that works well. This reduces the chances of any side effects. &nbsp;",
"     </p>",
"     <p>",
"      Some examples of inhaled steroids are",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?38/37/39504?source=see_link\">",
"       budesonide",
"      </a>",
"      (brand name: Pulmicort Flexhaler&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?37/53/38736?source=see_link\">",
"       ciclesonide",
"      </a>",
"      (brand name: Alvesco&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?41/1/42000?source=see_link\">",
"       fluticasone",
"      </a>",
"      (brand name: Flovent&reg; HFA), and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?40/57/41872?source=see_link\">",
"       mometasone",
"      </a>",
"      (brand name: Asmanex Twisthaler&reg;).",
"     </p>",
"     <p>",
"      Some people do not use their steroid inhaler or don&rsquo;t give their child his or her steroid medicine. This is because they worry about the side effects of steroids or do not &ldquo;feel&rdquo; the medicine working. But the truth is that not using a steroid inhaler is much riskier than any side effects it might cause. Inhaled steroids help keep asthma attacks from starting. These attacks can be dangerous and even cause death. Plus, asthma damages the lungs over time. Inhaled steroids can prevent some of that damage. You might not feel any different when you take this medicine, but that does not mean it is not working. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24479318\">",
"      <span class=\"h1\">",
"       Long-acting beta agonists (LABAs)",
"      </span>",
"      &nbsp;&mdash;&nbsp;Long-acting beta agonists are long-term controller medicines. They relax the muscles around the airways like short-acting beta agonists (SABAs) do. But the effects last much longer. You should only use a LABA at the same time as an inhaled steroid medicine.",
"     </p>",
"     <p>",
"      Medicines that have a LABA and steroid in 1 inhaler include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?41/1/42000?source=see_link\">",
"       fluticasone",
"      </a>",
"      with",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?39/25/40341?source=see_link\">",
"       salmeterol",
"      </a>",
"      (brand names: Advair Diskus&reg;, Advair&reg; HFA) and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?38/37/39504?source=see_link\">",
"       budesonide",
"      </a>",
"      with",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?22/56/23430?source=see_link\">",
"       formoterol",
"      </a>",
"      (brand name: Symbicort&reg;)",
"     </p>",
"     <p>",
"      Some LABAs come in a separate inhaler, but you",
"      <strong>",
"       must",
"      </strong>",
"      take them at the same time as a steroid medicine. Examples of LABAs are",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?39/25/40341?source=see_link\">",
"       salmeterol",
"      </a>",
"      (brand name: Serevent&reg; Diskus&reg;) and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?22/56/23430?source=see_link\">",
"       formoterol",
"      </a>",
"      (brand name: Foradil&reg; Aerolizer&reg;).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24479335\">",
"      <span class=\"h1\">",
"       Leukotriene modifiers",
"      </span>",
"      &nbsp;&mdash;&nbsp;Leukotriene modifiers are long-term controller medicines you take in a pill. They reduce inflammation and mucus and relax the muscles around the airways. These medicines don&rsquo;t work for everyone. They are not as strong as inhaled steroid medicines. &nbsp;",
"     </p>",
"     <p>",
"      Some examples of leukotriene modifiers are",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?13/18/13605?source=see_link\">",
"       montelukast",
"      </a>",
"      (brand name: Singulair&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?36/57/37780?source=see_link\">",
"       zafirlukast",
"      </a>",
"      (brand name: Accolate&reg;), or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/1/14357?source=see_link\">",
"       zileuton",
"      </a>",
"      (brand name: Zyflo&reg;).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24479352\">",
"      <span class=\"h1\">",
"       Steroids that come in pills",
"      </span>",
"      &nbsp;&mdash;&nbsp;If other asthma medicines do not work well, you might need to take steroid pills for a few days or weeks. Some people with severe asthma take steroid pills for several months or longer. They might need to take pills every day or every other day. Some examples of steroid pills for asthma are",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"       prednisone",
"      </a>",
"      and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/5/14422?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24479368\">",
"      <span class=\"h1\">",
"       Omalizumab (brand name: Xolair&reg;)",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your asthma is caused by allergies and inhaled steroids do not work well, your doctor might give you this medicine. It comes in a shot. The medicine lowers or stops the allergic reaction, and this can help asthma. It is only for people with moderate or very bad asthma.",
"     </p>",
"     <p>",
"      If you would like more detailed information, including information on the side effects caused by specific medicines, ask your doctor or nurse for information from Lexicomp, available through UpToDate.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24479384\">",
"      <span class=\"h1\">",
"       What else should I know about asthma medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Take all the medicines your doctor prescribes, exactly how you are supposed to take them. Remember, your controller medicines are helping you even if you do not feel them working. Use your asthma &ldquo;action plan&rdquo; if you have one. An action plan is a list of instructions that tells you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Which medicines to use every day",
"       </li>",
"       <li>",
"        Which ones to take if your symptoms get worse",
"       </li>",
"       <li>",
"        When to get help or call 9-1-1",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you do not have an asthma action plan, ask your doctor whether you need one.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24479401\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=see_link\">",
"       Patient information: Asthma in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=see_link\">",
"       Patient information: Asthma in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=see_link\">",
"       Patient information: Inhalers (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=see_link\">",
"       Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/47/9970?source=see_link\">",
"       Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"       Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=see_link\">",
"       Patient information: Asthma treatment in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/22/30052?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16117 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30052=[""].join("\n");
var outline_f29_22_30052=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24479256\">",
"      What do asthma medicines do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24479271\">",
"      Which medicines might I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24479286\">",
"      Short-acting beta agonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24479301\">",
"      Inhaled steroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24479318\">",
"      Long-acting beta agonists (LABAs)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24479335\">",
"      Leukotriene modifiers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24479352\">",
"      Steroids that come in pills",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24479368\">",
"      Omalizumab (brand name: Xolair&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24479384\">",
"      What else should I know about asthma medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24479401\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16117\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/52/837\">",
"      Asthma and its treatment",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/35/37439\">",
"       Metered dose inhaler",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=related_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=related_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=related_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=related_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/47/9970?source=related_link\">",
"      Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=related_link\">",
"      Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=related_link\">",
"      Patient information: Inhalers (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_22_30053="In utero fetal CMV infection";
var content_f29_22_30053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    In-utero cytomegalovirus infection at 23 postmenstrual weeks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panels A through C are serial coronal sections from anterior to posterior showing dilation of the lateral ventricles and periventricular calcifications. Panel D is an oblique section showing the dilation of the lateral ventricles, the dysmorphic choroid plexus, and periventricular calcifications.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30053=[""].join("\n");
var outline_f29_22_30053=null;
var title_f29_22_30054="Invasive hemodynamic tracing HCM with LVOT obstruction";
var content_f29_22_30054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Invasive hemodynamic tracing obtained during cardiac catheterization in a patient with hypertrophic cardiomyopathy (HCM) with left ventricular outflow tract (LVOT) obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are four surface ECG leads and the intracardiac pressure tracing obtained during cardiac catheterization. The systolic pressure in the left ventricle (LV) is 200 mmHg. When the catheter is pulled back to the LV outflow tract (LVOT), the LV systolic pressure falls to 100 mmHg, indicating that the pressure gradient across the LVOT is 100 mmHg. The aortic systolic pressure is also 100 mmHg, indicating that there is no gradient across the aortic valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lameh Fananapazir, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30054=[""].join("\n");
var outline_f29_22_30054=null;
var title_f29_22_30055="Acute and chronic gastritis due to Helicobacter pylori";
var content_f29_22_30055=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute and chronic gastritis due to Helicobacter pylori",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/22/30055/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30055/contributors\">",
"     Pamela J Jensen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30055/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/22/30055/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30055/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/22/30055/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30055/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/22/30055/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 6, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the gastric mucosa is associated with epithelial cell damage and regeneration. The term gastritis is used to denote inflammation associated with mucosal injury. However, epithelial cell injury and regeneration are not always accompanied by mucosal inflammation. This distinction has caused considerable confusion since gastritis is often used to describe endoscopic or radiologic characteristics of the gastric mucosa rather than specific histologic findings. Epithelial cell damage and regeneration without associated inflammation is referred to as \"gastropathy\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=see_link\">",
"     \"Classification and diagnosis of gastritis and gastropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causes, natural history, and therapeutic implications of gastropathy differ from gastritis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastropathy is usually caused by irritants such as drugs (eg, nonsteroidal antiinflammatory agents), alcohol, bile, circulatory failure, and chronic congestion.",
"     </li>",
"     <li>",
"      Gastritis is usually due to infectious agents (such as Helicobacter pylori) and autoimmune and hypersensitivity reactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most classification systems distinguish acute, short-term from chronic, long-term disease. The terms acute and chronic are also used to describe the type of inflammatory cell infiltrate. Acute (\"active\") inflammation is usually associated with neutrophilic infiltration, while chronic inflammation is usually characterized by mononuclear cells, chiefly lymphocytes, plasma cells and macrophages. A practical clinicopathologic framework for the classification of gastritis and gastropathy based upon these factors can be proposed (",
"    <a class=\"graphic graphic_table graphicRef73286 \" href=\"UTD.htm?38/54/39788\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute and chronic gastritis due to Helicobacter pylori will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Although described separately, most patients with Helicobacter pylori infection will show features of both acute and chronic gastritis. The other forms of gastritis and gastropathy and other issues related to H. pylori are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=see_link\">",
"     \"Classification and diagnosis of gastritis and gastropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/46/9959?source=see_link\">",
"     \"Helicobacter pylori and gastroesophageal reflux disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4809?source=see_link\">",
"     \"Pathophysiology of and immune response to Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HELICOBACTER PYLORI GASTRITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65358059\">",
"    <span class=\"h2\">",
"     Acute Helicobacter pylori gastritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of H. pylori to cause acute gastritis was demonstrated most clearly after healthy volunteers ingested the organisms and developed a mild illness (consisting of epigastric pain, nausea, and vomiting without fever) associated with acute inflammatory changes on gastric biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Acute infection was also demonstrated in volunteers undergoing gastric secretory studies who were inadvertently infected by contaminated equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. These cases also demonstrated that acute infection is associated with the development of hypochlorhydria, a phenomenon that was suspected to be caused by an infectious agent and was referred to as \"epidemic hypochlorhydria.\" (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4809?source=see_link\">",
"     \"Pathophysiology of and immune response to Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the high prevalence of chronic H. pylori gastritis, few examples of spontaneous acute infection have been recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. This is not surprising since the majority of patients who develop dyspeptic complaints (which may signal acute infection) are not immediately investigated; furthermore, the initial infection occurring in the community probably produces few or no symptoms in the majority of individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Endoscopic and histopathologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endoscopic appearance of acute H. pylori gastritis is variable and, in severe cases, can resemble lymphoma or carcinoma. Early after infection, Helicobacter pylori gastritis preferentially involves the gastric antrum. Histologic changes of acute Helicobacter pylori gastritis include intense neutrophilic infiltration of the mucous neck region and lamina propria. When severe, pit abscesses occur, along with mucin loss, erosion of the juxtaluminal cytoplasm, and desquamation of surface foveolar cells. Both the neutrophils and the bacteria are responsible for destruction of the epithelium. Acute gastritis almost always evolves into active chronic gastritis unless treated with appropriate antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic Helicobacter pylori gastritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic H. pylori gastritis affects two-thirds of the world's population and is one of the most common chronic inflammatory disorders of humans [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/13\">",
"     13",
"    </a>",
"    ]. The major clinical associations with chronic H. pylori gastritis are peptic ulcer disease and, less commonly, gastric cancer and MALT lymphoma. (See appropriate topic reviews.) An association between chronic H. pylori infection and dyspepsia remains controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"     \"Functional dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    H. pylori organisms reside primarily in the unstirred layer of gastric mucus, adjacent to epithelial cells at the mucosal surface and in gastric pits (",
"    <a class=\"graphic graphic_picture graphicRef64354 graphicRef63916 \" href=\"UTD.htm?37/55/38778\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/14\">",
"     14",
"    </a>",
"    ]. Gastric glands are usually not involved. The epithelial localization reflects the affinity of H. pylori organisms for gastric mucous cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. H. pylori organisms do not attach to small intestinal or other gastric epithelial cell types. The organisms are uncommonly found in the lamina propria, except possibly in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4809?source=see_link\">",
"     \"Pathophysiology of and immune response to Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The organisms can be detected in both the antrum and the body of the stomach in the majority of infected patients. The following represents the approximate frequency of H. pylori localization within the stomach, based upon the collective experience of several investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antrum and body &ndash; 80 percent",
"     </li>",
"     <li>",
"      Antrum only &ndash; 8 percent",
"     </li>",
"     <li>",
"      Body only &ndash; 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first two patterns are associated with Helicobacter pylori and the last pattern is associated with Helicobacter pylori infection, modified by PPIs or marked atrophy and intestinal metaplasia. The usual natural history of Helicobacter pylori gastritis is of an antral predominant early stage of infection with only minimal corpus involvement. This stage is associated with exaggerated gastrin release and reduced somatostatin release, precipitating an increase in acid secretion, enough to cause duodenal ulcers in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With continued inflammation, gastrin producing (G) cells and acid producing parietal cells are gradually lost, precipitating a fall in acid secretion and the development of atrophy with intestinal metaplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/20\">",
"     20",
"    </a>",
"    ]. These changes facilitate the proximal migration of the bacteria, leading to corpus gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, the natural history of Helicobacter pylori gastritis is of diffuse antral inflammation spreading to the corpus, resulting in an atrophic front of advancing corpus injury with concomitant reduction in acid secretion. This scenario is accelerated with low acid secretion states such as chronic therapy with PPIs. However, this evolution is not inevitable since it can be modified by treatment.",
"   </p>",
"   <p>",
"    Patients in whom Helicobacter pylori colonization is heaviest in the gastric body may differ from those with antral predominant infection. Duodenal ulcers are typically associated with antral predominant gastritis, little or no atrophy, and normal or increased acid secretion. By contrast, gastric ulcers and gastric cancer are typically associated with extensive gastritis, widespread intestinal metaplasia and hypochlorhydria [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Histopathologic diagnosis of Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;In current practice, noninvasive testing (eg, serology or stool antigen assay) is generally used to establish the diagnosis of H. pylori infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .) A major role for histopathology is in the following indications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diagnosing H. pylori infection in patients taking a proton pump inhibitor (PPI) as PPIs can reduce the sensitivity of some of the noninvasive assays. This effect that may be due to the antimicrobial activity of these drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To establish gastritis.",
"     </li>",
"     <li>",
"      To detect associated abnormalities such as intestinal metaplasia and mucosa-associated lymphoid tissue (MALT) lymphoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The variable distribution of H. pylori in the stomach, and the attenuated growth observed during treatment with PPIs has implications for optimal sites and the number of biopsy specimens that should be obtained to establish the diagnosis of Helicobacter pylori. In one study, the combination of four biopsy sites (lesser and greater curvature of the mid antrum, lesser and greater curvature of the mid body) was found to be optimal for the detection of H. pylori and the assessment of the extent of atrophic gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A definitive histopathologic diagnosis of H. pylori infection depends upon the demonstration of the typical spiral shaped bacilli on a biopsy specimen. During treatment, Helicobacter pylori bacteria may lose their typical spiral shape and assume new forms, including U-shaped, rod-like, and coccoid forms. The coccoid forms appear as round basophilic dots, 0.4 to 1.2 &micro;m in diameter. Proton pump inhibitors and other hypochlorhydric states facilitate survival of non-Helicobacter pylori bacteria, such that the presence of gastric organisms (including cocci) does not confirm the presence of Helicobacter infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/25\">",
"     25",
"    </a>",
"    ]. In such cases, the distinction requires immunohistochemistry for Helicobacter pylori.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Staining",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is frequently possible to identify H. pylori in standard hematoxylin and eosin preparations, this type of staining is unreliable and is",
"    <strong>",
"     not",
"    </strong>",
"    advised [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. A variety of better staining methods for H. pylori are available [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The quick Giemsa method (eg, Diff-Quik&reg;) is easy to use, inexpensive, and gives consistent results. It is the preferred method in many laboratories [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunostaining techniques are also available, and are highly sensitive and reliable (",
"      <a class=\"graphic graphic_picture graphicRef73081 \" href=\"UTD.htm?31/26/32164\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/29\">",
"       29",
"      </a>",
"      ]. They have a particular advantage in patients partially treated for Helicobacter pylori gastritis, a setting that can result in atypical (including coccoid) forms, which may mimic bacteria or cell debris on hematoxylin and eosin preparations.",
"     </li>",
"     <li>",
"      Silver stains (such Warthin-Starry and Genta methods), which were crucial to the original demonstration of H. pylori, [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/30\">",
"       30",
"      </a>",
"      ] are expensive and the results are not always reliable [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mucosal changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory changes in chronic H. pylori gastritis have been well described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/31\">",
"     31",
"    </a>",
"    ]. Acute and chronic inflammatory cells are concentrated in the upper part of the mucosa, beginning just below the surface epithelium and giving the appearance of superficial gastritis, particularly in oxyntic mucosa. This pattern is so characteristic that the observer can suspect H. pylori gastritis even at the lowest magnifications.",
"   </p>",
"   <p>",
"    The chronic inflammatory elements in H. pylori gastritis primarily consist of lymphocytes and plasma cells, scattered macrophages, and often increased eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/31\">",
"     31",
"    </a>",
"    ]. Lymphoid follicles are frequently present. They represent an immune response to the bacteria and their presence provides a useful marker for Helicobacter pylori infection (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Significance of lymphoid follicles'",
"    </a>",
"    below). Similarly, a prominence of plasma cells is a valuable clue to H. pylori infection.",
"   </p>",
"   <p>",
"    The acute (active) inflammatory component consists of neutrophilic infiltration of the surface and foveolar epithelium and the lamina propria, usually in scattered foci, with the frequent presence of small pit abscesses.",
"   </p>",
"   <p>",
"    The intensity of the inflammation varies among patients and sometimes from specimen to specimen in the same patient. Active inflammation is somewhat more common in antral than in oxyntic H. pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/32\">",
"     32",
"    </a>",
"    ]. Although casual observation reveals no obvious relation between the numbers of organisms and the severity of the acute or chronic inflammation, a correlation with active gastritis has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Significance of lymphoid follicles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoid follicles represent an immune response to the organism, and are composed of aggregates of lymphocytes and other lymphoid cells associated with a central germinal center made up of larger, paler mononuclear cells. They appear within one week after the onset of acute H. pylori infection, and are uncommon in non-H. pylori-infected gastric mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/8,34\">",
"     8,34",
"    </a>",
"    ]. The number of lymphoid follicles correlates with the titer of serum IgG anti-H. pylori antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymphoid follicles accompanying H. pylori gastritis are involved in the genesis of primary gastric lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The pathogenesis may involve stimulation of B cells with the ability for unsuppressed proliferation by activated T cells within the follicles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Mucosal histopathology after eradication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute inflammation associated with chronic H. pylori gastritis improves dramatically after eradication of the organisms with antibiotics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutrophils disappear rapidly; the persistence of even small numbers of neutrophils may be predictive of relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lymphocytes and eosinophils decrease more slowly, and some chronic inflammation can be seen after one year. Lymphoid follicles are the slowest to disappear, and usually remain present throughout the stomach for more than one year [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intestinal metaplasia and atrophy usually do not resolve by one year [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/39\">",
"       39",
"      </a>",
"      ]. However, eradication may help prevent the development of further gastric atrophy and intestinal metaplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fibrosis and architectural distortion, including foveolar hyperplasia, may persist long after H. pylori infection is eliminated and, in our experience, often resembles chemical gastropathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Iron deficiency anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency anemia (without evidence of blood loss from the gastrointestinal tract or other sources) has been described in association with H. pylori gastritis and may respond to eradication of H. pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/41\">",
"     41",
"    </a>",
"    ]. The pathogenesis is incompletely understood, but may relate to the organism's dependence upon iron as a growth factor or the presence of H. pylori-associated gastric atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65358291\">",
"    <span class=\"h1\">",
"     HELICOBACTER HEILMANNII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious agents other than H. pylori have been associated with gastritis. One such agent is Helicobacter heilmannii (formerly Gastrospirillum hominis). H. heilmannii is an uncommon zoonotic infection that has been associated with gastritis (typically mild), duodenal ulcers, acute gastric mucosal lesions, mucosa-associated lymphoid tissue lymphoma, and gastric carcinoma. The organism is twice as long as H. pylori (5 to 9 microns) and has five to seven tight spirals. Immunohistochemical stains for H. pylori also react with H. heilmannii. Treatment is similar [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30055/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=see_link\">",
"       \"Patient information: H. pylori infection (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/46/1763?source=see_link\">",
"       \"Patient information: Gastritis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Helicobacter pylori is almost always accompanied by gastritis and the diagnosis should be suspect in its absence.",
"     </li>",
"     <li>",
"      Helicobacter pylori gastritis typically begins as a diffuse antral gastritis, which subsequently spreads to the gastric corpus if untreated. Changes of chronic active gastritis may be associated with intestinal metaplasia (atrophy). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Chronic Helicobacter pylori gastritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic use of proton pump inhibitors (PPIs) may facilitate proximal migration of the organisms leading to corpus gastritis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Chronic Helicobacter pylori gastritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute inflammation disappears rapidly with treatment, but the chronic inflammation, including lymphoid follicles, can persist for years. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Significance of lymphoid follicles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Four different biopsy sites are recommended for the optimal detection of Helicobacter pylori. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Histopathologic diagnosis of Helicobacter pylori'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunohistochemistry may be necessary for the detection of Helicobacter pylori organisms in patients on antibiotic, chronic PPI therapy or with other hypochlorhydric states that predispose to gastric bacterial overgrowth. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Staining'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/1\">",
"      Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/2\">",
"      Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology 1995; 108:917.",
"     </a>",
"    </li>",
"    <li>",
"     Yardley JH, Hendrix TR. Gastritis, duodenitis, and associated ulcerative lesions. In: Textbook of Gastroenterology, Yamada T, Alpers DH, Owyang C, et al (Eds), Lippincott, Philadelphia 1995. p.1456.",
"    </li>",
"    <li>",
"     Yardley JH, Hendrix TR. Gastritis, duodenitis, and associated ulcerative lesions. In: Textbook of Gastroenterology, 3rd ed, Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE (Eds), Lippincott, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/5\">",
"      Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 1985; 142:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/6\">",
"      Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987; 82:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/7\">",
"      Ramsey EJ, Carey KV, Peterson WL, et al. Epidemic gastritis with hypochlorhydria. Gastroenterology 1979; 76:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/8\">",
"      Graham DY, Alpert LC, Smith JL, Yoshimura HH. Iatrogenic Campylobacter pylori infection is a cause of epidemic achlorhydria. Am J Gastroenterol 1988; 83:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/9\">",
"      Gledhill T, Leicester RJ, Addis B, et al. Epidemic hypochlorhydria. Br Med J (Clin Res Ed) 1985; 290:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/10\">",
"      Salmeron M, Desplaces N, Lavergne A, Houdart R. Campylobacter-like organisms and acute purulent gastritis. Lancet 1986; 2:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/11\">",
"      Frommer DJ, Carrick J, Lee A, Hazell SL. Acute presentation of Campylobacter pylori gastritis. Am J Gastroenterol 1988; 83:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/12\">",
"      Rocha GA, Queiroz DM, Mendes EN, et al. Helicobacter pylori acute gastritis: histological, endoscopical, clinical, and therapeutic features. Am J Gastroenterol 1991; 86:1592.",
"     </a>",
"    </li>",
"    <li>",
"     Odze RD, Goldblum JR. Inflammatory disorders of the stomach. In: Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas, Lash RH, Lauwers GY, et al.  (Eds), Saunders, Philadelphia 2009. p.285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/14\">",
"      Hazell SL, Lee A, Brady L, Hennessy W. Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. J Infect Dis 1986; 153:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/15\">",
"      Noach LA, Rolf TM, Tytgat GN. Electron microscopic study of association between Helicobacter pylori and gastric and duodenal mucosa. J Clin Pathol 1994; 47:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/16\">",
"      Falk P, Roth KA, Bor&eacute;n T, et al. An in vitro adherence assay reveals that Helicobacter pylori exhibits cell lineage-specific tropism in the human gastric epithelium. Proc Natl Acad Sci U S A 1993; 90:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/17\">",
"      Meiselman MS, Miller-Catchpole R, Christ M, Randall E. Campylobacter pylori gastritis in the acquired immunodeficiency syndrome. Gastroenterology 1988; 95:209.",
"     </a>",
"    </li>",
"    <li>",
"     Paull G, Yardley JH. Pathology of C pylori-associated gastric and esophageal lesions. In: Campylobacter Pylori in Gastritis and Peptic Ulcer Disease, Blaser MJ (Ed), Igaku-Shoin, New York 1989. p.73.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/19\">",
"      Graham DY, Opekun A, Lew GM, et al. Helicobacter pylori-associated exaggerated gastrin release in duodenal ulcer patients. The effect of bombesin infusion and urea ingestion. Gastroenterology 1991; 100:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/20\">",
"      V&auml;&auml;n&auml;nen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003; 15:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/21\">",
"      Gutierrez O, Kim JG, Akamatsu T, et al. Geographic differences in the distribution of intestinal metaplasia in duodenal ulcer patients. Am J Gastroenterol 2001; 96:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/22\">",
"      Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52:6735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/23\">",
"      Jonkers D, Stobberingh E, Stockbr&uuml;gger R. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother 1996; 37:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/24\">",
"      Satoh K, Kimura K, Taniguchi Y, et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol 1998; 93:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/25\">",
"      El-Zimaity H. How to interpret biopsies for \"gastritis\". Path Case Rev 2008; 13:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/26\">",
"      Agbamu DA. Staining for Helicobacter pylori: an E-mail survey. Hum Pathol 1997; 28:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/27\">",
"      Molyneux AJ, Harris MD. Helicobacter pylori in gastric biopsies--should you trust the pathology report? J R Coll Physicians Lond 1993; 27:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/28\">",
"      Madan E, Kemp J, Westblom TU, et al. Evaluation of staining methods for identifying Campylobacter pylori. Am J Clin Pathol 1988; 90:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/29\">",
"      Ashton-Key M, Diss TC, Isaacson PG. Detection of Helicobacter pylori in gastric biopsy and resection specimens. J Clin Pathol 1996; 49:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/30\">",
"      Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/31\">",
"      Karttunen T, Niemel&auml; S, Lehtola J, et al. Campylobacter-like organisms and gastritis: histopathology, bile reflux, and gastric fluid composition. Scand J Gastroenterol 1987; 22:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/32\">",
"      Johnston BJ, Reed PI, Ali MH. Prevalence of Campylobacter pylori in duodenal and gastric mucosa--relationship to inflammation. Scand J Gastroenterol Suppl 1988; 142:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/33\">",
"      Wyatt JI, Rathbone BJ, Heatley RV. Local immune response to gastric Campylobacter in non-ulcer dyspepsia. J Clin Pathol 1986; 39:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/34\">",
"      Genta RM, Hamner HW, Graham DY. Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol 1993; 24:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/35\">",
"      Fox JG, Correa P, Taylor NS, et al. Campylobacter pylori-associated gastritis and immune response in a population at increased risk of gastric carcinoma. Am J Gastroenterol 1989; 84:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/36\">",
"      Isaacson PG, Spencer J. Is gastric lymphoma an infectious disease? Hum Pathol 1993; 24:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/37\">",
"      Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/38\">",
"      Genta RM, Lew GM, Graham DY. Changes in the gastric mucosa following eradication of Helicobacter pylori. Mod Pathol 1993; 6:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/39\">",
"      van der Hulst RW, van der Ende A, Dekker FW, et al. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology 1997; 113:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/40\">",
"      Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000; 119:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/41\">",
"      Yakoob J, Jafri W, Abid S. Helicobacter pylori infection and micronutrient deficiencies. World J Gastroenterol 2003; 9:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/42\">",
"      Cardenas VM, Mulla ZD, Ortiz M, Graham DY. Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol 2006; 163:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/43\">",
"      Annibale B, Marignani M, Monarca B, et al. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med 1999; 131:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/44\">",
"      Goddard AF, Logan RP, Atherton JC, et al. Healing of duodenal ulcer after eradication of Helicobacter heilmannii. Lancet 1997; 349:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/45\">",
"      al-Himyary AJ, Zabaneh RI, Zabaneh SS, Barnett S. Gastrospirillum hominis in acute gastric erosion. South Med J 1994; 87:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/46\">",
"      Morgner A, Bayerd&ouml;rffer E, Meining A, et al. Helicobacter heilmannii and gastric cancer. Lancet 1995; 346:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/47\">",
"      Morgner A, Lehn N, Andersen LP, et al. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000; 118:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30055/abstract/48\">",
"      Okiyama Y, Matsuzawa K, Hidaka E, et al. Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients. Pathol Int 2005; 55:398.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 31 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-8B005171DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30055=[""].join("\n");
var outline_f29_22_30055=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HELICOBACTER PYLORI GASTRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65358059\">",
"      Acute Helicobacter pylori gastritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Endoscopic and histopathologic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic Helicobacter pylori gastritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Histopathologic diagnosis of Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Staining",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mucosal changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Significance of lymphoid follicles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Mucosal histopathology after eradication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Iron deficiency anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H65358291\">",
"      HELICOBACTER HEILMANNII",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/31\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/31|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/26/18858\" title=\"picture 1A\">",
"      H pylori gastritis Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/15/30964\" title=\"picture 1B\">",
"      H pylori on crypt cells Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/26/32164\" title=\"picture 2\">",
"      H pylori immunostain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/31|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/54/39788\" title=\"table 1\">",
"      Classification of gastritis and gastropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=related_link\">",
"      Association between Helicobacter pylori infection and duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=related_link\">",
"      Classification and diagnosis of gastritis and gastropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=related_link\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/46/9959?source=related_link\">",
"      Helicobacter pylori and gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4809?source=related_link\">",
"      Pathophysiology of and immune response to Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/46/1763?source=related_link\">",
"      Patient information: Gastritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_22_30056="The relationship between IgE and allergic disease";
var content_f29_22_30056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The relationship between IgE and allergic disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/22/30056/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30056/contributors\">",
"     Jeff Stokes, MD, FAAAAI, FACAAI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30056/contributors\">",
"     Thomas B Casale, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/22/30056/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30056/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/22/30056/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30056/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/22/30056/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5310808\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen-specific IgE is integral to the pathogenesis of allergic disorders. However, the utility of measuring total serum IgE or allergen-specific IgE for purposes of diagnosis and management is variable. It is important to recognize that levels of total IgE rarely provide information about IgE to specific allergens, and that the presence of IgE to a specific allergen does not necessarily equate to a clinically meaningful allergic response to that substance. It is also necessary to demonstrate that the individual develops appropriate signs and symptoms upon exposure to the allergen in question.",
"   </p>",
"   <p>",
"    This topic will review basic concepts concerning the generation of the allergic response and provide an overview of the roles of total and allergen-specific IgE in various allergic diseases. The biology of IgE and the diagnosis of specific allergic diseases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=see_link\">",
"     \"The biology of IgE\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1366636\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms atopy, sensitization, and allergy are often used loosely in the medical literature, although each has a distinct definition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1366629\">",
"    <span class=\"h2\">",
"     Atopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopy is the genetic predilection to produce specific IgE following exposure to allergens. At a cellular level, atopy appears to result, in part, from a predisposition toward a certain response on the part of CD4+ T helper cells, called a Th type 2 (Th2) response [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/1\">",
"     1",
"    </a>",
"    ]. Th2 cells secrete large quantities of IL-4 and IL-13, which promote the production of allergen-specific IgE by plasma cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link\">",
"     \"T helper subsets: Differentiation and role in disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=see_link&amp;anchor=H264545938#H264545938\">",
"     \"The biology of IgE\", section on 'Regulation of synthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1366655\">",
"    <span class=\"h2\">",
"     Sensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensitization refers to the production of allergen-specific IgE. Sensitization to an allergen is",
"    <strong>",
"     not",
"    </strong>",
"    synonymous with being allergic to that allergen, because individuals may produce IgE to allergens in a given substance, but not develop symptoms upon exposure to that substance. It is unclear why some individuals demonstrate only sensitization while others have active allergic disease.",
"   </p>",
"   <p>",
"    Sensitization is usually demonstrated by skin testing or in vitro immunoassays for IgE to specific allergens (sometimes referred to as RAST testing, although this term describes an antiquated form of the test). Thus, sensitization is necessary but not sufficient for the development of allergic disease. Because a person can be sensitized to an allergen but not react to it upon exposure, it is prudent to limit allergy testing to those allergens which are implicated by the clinical history.",
"   </p>",
"   <p>",
"    The production of allergen-specific IgE is summarized briefly here in simplified form and reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=see_link&amp;anchor=H13745053#H13745053\">",
"     \"The biology of IgE\", section on 'Synthesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a substance enters the body (through ingestion, inhalation, or injection), it is degraded, and allergens (usually proteins but occasionally carbohydrates) are taken up by antigen presenting cells, including macrophages, CD1+ dendritic cells, B cells, and possibly epithelial cells. Antigen presenting cells further degrade the allergen and present peptide fragments of it on the cell surface, in the setting of class II (MHC) molecules. The",
"    <span class=\"nowrap\">",
"     peptide/MHC",
"    </span>",
"    II complexes are recognized by Th2 cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=see_link\">",
"     \"Antigen presenting cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Th2 cells then interact with B cells and, in the presence of various costimulatory signals, stimulate the B cell to mature into a plasma cell that produces IgE specific to the component of the allergen in question. B cell maturation primarily occurs within mucosal lymphoid tissue.",
"   </p>",
"   <p>",
"    After IgE antibodies specific for a certain allergen are synthesized and secreted, they diffuse throughout the body, binding to high-affinity receptors (Fc&epsilon;RI) on mast cells in the tissues and basophils in the circulating blood (",
"    <a class=\"graphic graphic_figure graphicRef55328 \" href=\"UTD.htm?41/30/42469\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1366662\">",
"    <span class=\"h2\">",
"     Allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals are considered to have clinically significant allergy or allergic disease when they have both allergen-specific IgE",
"    <strong>",
"     and",
"    </strong>",
"    develop symptoms upon exposure to substances containing that allergen. Therefore, greater numbers of people are sensitized to an allergen then are clinically allergic to it. This was illustrated in the National Health and Nutrition Examination Survey (NHANES) 2005-6, in which over 8000 people from the general population of the United States were interviewed and tested (using in vitro blood tests) for sensitization to 19 common inhalant allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/2\">",
"     2",
"    </a>",
"    ]. Specific IgE antibodies to at least one allergen were present in 44 percent, whereas only 34 percent had symptoms suggestive of allergic disease. Similar findings have been documented for food allergy. In a population-based birth cohort study in the United Kingdom, 12 percent of children were sensitized to peanut at eight years of age, but only 2 percent were allergic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A sensitized person may develop symptoms when re-exposed to the relevant allergen, if the allergen is able to bind to IgE antibodies on the surface of mast cells and basophils in sufficient numbers to cause clustering (called cross-linking) of the IgE molecules. Cross-linking of enough IgE receptors results in the generation of activating signals. Upon activation, mast cells and basophils release preformed and newly-formed chemical and protein mediators, which directly and indirectly lead to the signs and symptoms of allergic reactions. These mediators include histamine, prostaglandins, leukotrienes, platelet activating factor, cytokines, and others. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=see_link\">",
"     \"Mast cell derived mediators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common allergic diseases include allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, stinging-insect venom allergy, and drug allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4432104\">",
"    <span class=\"h2\">",
"     The atopic march",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopic dermatitis (AD), allergic rhinitis, and asthma often affect the same patients and develop in temporal succession. This progression from atopic dermatitis in infancy to allergic rhinitis and asthma in childhood and young adulthood is referred to as the &ldquo;allergic march&rdquo; or &ldquo;atopic march&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Nearly 80 percent of children with AD will subsequently develop allergic rhinitis or asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25256003\">",
"    <span class=\"h1\">",
"     RELATIONSHIPS BETWEEN TOTAL IgE LEVELS AND ALLERGIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A total serum IgE level of 100 international units",
"    <span class=\"nowrap\">",
"     (IU)/mL",
"    </span>",
"    is typically cited as the upper limit of normal in older adolescents and adults. Elevations in total serum IgE are seen in several types of disorders, including allergic diseases, some primary immunodeficiencies, parasitic and viral infections, certain inflammatory diseases, some malignancies, and a handful of other diseases (",
"    <a class=\"graphic graphic_table graphicRef83457 \" href=\"UTD.htm?29/49/30492\">",
"     table 1",
"    </a>",
"    ). Thus, elevated total serum IgE is not specific to allergic disease. Studies concerning allergic diseases are reviewed here, while studies of IgE in other diseases are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=see_link&amp;anchor=H13745149#H13745149\">",
"     \"The biology of IgE\", section on 'Increased total IgE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1127469\">",
"    <span class=\"h2\">",
"     Elevated total serum IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with allergic disorders have elevated levels of total IgE; however, there is no specific cutoff value that discriminates patients with allergic disease from those without, and there is considerable overlap [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Thus, total IgE by itself is rarely adequate to diagnose allergic disease. The following studies are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adults with IgE &gt;66",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      have a 37-fold greater risk of having allergen-specific IgE antibodies to aeroallergens compared to those patients with the lowest levels of total IgE [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study, school-aged children had a mean IgE level of 51",
"      <span class=\"nowrap\">",
"       IU/mL.",
"      </span>",
"      Children with both atopic dermatitis and asthma had mean IgE levels of 985",
"      <span class=\"nowrap\">",
"       IU/mL,",
"      </span>",
"      asthma alone 305",
"      <span class=\"nowrap\">",
"       IU/mL,",
"      </span>",
"      eczema alone 273",
"      <span class=\"nowrap\">",
"       IU/mL,",
"      </span>",
"      and allergic rhinitis 171",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among atopic patients of all ages, those with atopic dermatitis tend to have the highest IgE levels followed by atopic asthma, perennial allergic rhinitis, and seasonal allergic rhinitis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using a total serum IgE level of 100",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      to discriminate allergic from nonallergic patients, the sensitivity was 78 percent for patients with asthma and 60 percent for rhinitis, but 20 percent of patients were misclassified [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15831609\">",
"    <span class=\"h2\">",
"     Low or normal levels of total serum IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors of UpToDate know of no studies to suggest that low levels of total serum IgE can be used to exclude the presence of atopic disease, because of the wide overlap in total serum IgE among atopic and nonatopic populations. Patients with low or normal serum IgE levels could still have local production of allergen-specific IgE in the tissues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=see_link&amp;anchor=H1397010#H1397010\">",
"     \"The biology of IgE\", section on 'Localized IgE production'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1128141\">",
"    <span class=\"h2\">",
"     Utility in predicting the development of allergic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because elevations in total serum IgE are associated with established allergic disease, researchers have questioned whether IgE levels predict its development. Studies suggest that elevated total IgE is associated with an increased risk of allergic disease, although there is significant overlap between affected individuals and normals, such that the measurement is most useful in the context of population studies, rather than in the diagnosis or management of an individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1128173\">",
"    <span class=\"h3\">",
"     Cord blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cord blood IgE levels have been studied in an attempt to identify newborns who are at increased risk for the development of allergic disease. Maternal IgE does not normally cross the placenta, although fetal cord blood can be contaminated by maternal blood during late pregnancy and delivery and must be carefully collected [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/14\">",
"     14",
"    </a>",
"    ]. The majority of studies suggest that elevated total IgE in cord blood is an indicator of higher risk. As examples, studies have shown that newborns with elevated cord IgE levels had an increased risk of developing urticarial food reactions at one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/15\">",
"     15",
"    </a>",
"    ], atopic dermatitis by age two [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/16\">",
"     16",
"    </a>",
"    ], allergen sensitization and wheezing at seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/17\">",
"     17",
"    </a>",
"    ], or allergic rhinitis by 11 and 20 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/18\">",
"     18",
"    </a>",
"    ]. However, no relationship was found between cord blood IgE levels and the development of asthma, allergic rhinitis or atopic dermatitis by the time the child was 18 to 21 years of age despite a modest association with total IgE levels at those ages in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=see_link&amp;anchor=H13745125#H13745125\">",
"     \"The biology of IgE\", section on 'Childhood levels'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1126963\">",
"    <span class=\"h3\">",
"     Childhood IgE levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated IgE in young children appears to be an early predictor of the subsequent development of allergen-specific IgE and of allergic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the clinical utility of this is limited by the extensive overlap between normals and atopic individuals, and the fact that patients with asthma have higher total IgE compared with nonasthmatics, regardless of atopic status. (See",
"    <a class=\"local\" href=\"#H25256003\">",
"     'Relationships between total IgE levels and allergic disease'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5310840\">",
"     'Asthma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1127398\">",
"    <span class=\"h3\">",
"     Timeline of sensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the presence of allergen-specific IgE precedes the onset of symptoms by several years. In a study of nearly 1000 college students, subjects were evaluated initially and again 7 and 16 years later using questionnaires and skin testing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/21\">",
"     21",
"    </a>",
"    ]. At the seven-year follow-up, subjects with prior positive skin tests demonstrated an increased risk of developing allergic rhinitis and asthma. When these same patients were reassessed 16 years later, a 2.3-fold greater risk of developing allergic rhinitis was found in those subjects with positive allergen skin tests [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/22\">",
"     22",
"    </a>",
"    ]. Positive allergy skin tests and allergic rhinitis increased the likelihood of developing asthma threefold.",
"   </p>",
"   <p>",
"    In a small minority of patients, sensitization occurs only in the affected tissues, presumably due to low levels of allergen-specific IgE being produced by local mucosal plasma cells. This phenomenon of local IgE production is termed &ldquo;entopy&rdquo;. In such patients, allergen-specific IgE is not demonstrable by either allergy skin testing or blood work, which presents diagnostic challenges. This is best described for some patients with rhinitis who have negative skin and in vitro tests for allergen-specific IgE, yet react to challenge with inhaled allergen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=see_link&amp;anchor=H11#H11\">",
"     \"Chronic nonallergic rhinitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1366692\">",
"    <span class=\"h1\">",
"     THE ROLE OF IgE IN SPECIFIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of total and allergen-specific IgE levels in pathogenesis and diagnosis differs among the leading allergic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5310840\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adults with asthma tend to have higher IgE levels than individuals without asthma, although there is no absolute cutoff that distinguishes between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/23\">",
"     23",
"    </a>",
"    ]. Conversely, nonatopic patients with high levels of IgE are more likely to have asthma than those with normal IgE levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/24\">",
"     24",
"    </a>",
"    ]. In one study, nonallergic patients with a total serum IgE level greater than 150",
"    <span class=\"nowrap\">",
"     IU/ml",
"    </span>",
"    were at a fivefold higher risk of having asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/25\">",
"     25",
"    </a>",
"    ]. Still, the increase in elevated total IgE in asthmatics compared to nonasthmatics is generally driven by atopic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased expression of the high affinity IgE receptor (Fc&epsilon;RI) has been demonstrated on cells in the airways of both atopic and nonatopic asthma patients compared to nonatopic control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. IgE positively regulates Fc&epsilon;RI levels, so both IgE and Fc&epsilon;RI tend to increase or decrease in parallel. Patients with atopic dermatitis and asthma are more likely than controls to have mutations in the alpha subunit of Fc&epsilon;R1 (the subunit that directly binds to IgE) associated with increased serum IgE levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In allergic patients with asthma, anti-IgE therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    ) improves symptoms, reduces exacerbations and medication requirements, and decreases multiple inflammatory markers, demonstrating the role of IgE in allergic asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link&amp;anchor=H7#H7\">",
"     \"Anti-IgE therapy\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5310848\">",
"    <span class=\"h3\">",
"     Lung function correlates with IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE levels correlate with asthma severity; serum IgE levels are proportionately higher in asthmatic patients with lower lung function (FEV1) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/31\">",
"     31",
"    </a>",
"    ]. This may also be true for allergen-specific IgE; in patients with lower respiratory symptoms to specific aeroallergens (eg, cat), levels of allergen-specific IgE correlated well with asthma symptoms and lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the key features of asthma is airway hyperresponsiveness, typically measured by bronchoprovocation challenges. In patients with asthma, elevated total IgE levels are associated with positive responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/33\">",
"     33",
"    </a>",
"    ]. Airway hyperresponsiveness in children correlates closely with total IgE level even after exclusion of children with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/34\">",
"     34",
"    </a>",
"    ]. However, airway hyperresponsiveness was more closely correlated to positive allergen skin test reactions than total IgE levels in children [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smoking is associated with increased IgE levels in a dose-dependent fashion, possibly due to the lack of expected decreases in IgE levels with aging [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/36\">",
"     36",
"    </a>",
"    ]. The inverse relationship between IgE levels and lung function was stronger in asthmatic patients in both current and never smokers, compared with nonasthmatic subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5310864\">",
"    <span class=\"h2\">",
"     Allergic bronchopulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic bronchopulmonary aspergillosis (ABPA) is one of the few disorders in which total IgE values are used directly in diagnosis and treatment. ABPA typically occurs in patients with asthma or cystic fibrosis. The ubiquitous mold",
"    <em>",
"     Aspergillus fumigatus",
"    </em>",
"    causes localized immunologic-mediated damage in the lung. Diagnostic features include increased total IgE (&gt;417",
"    <span class=\"nowrap\">",
"     kU/L",
"    </span>",
"    for patients with asthma and &gt;1000",
"    <span class=\"nowrap\">",
"     kU/L",
"    </span>",
"    for those with cystic fibrosis) and evidence of increased specific IgE and IgG to",
"    <em>",
"     A fumigatus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/38\">",
"     38",
"    </a>",
"    ]",
"    <em>",
"     .",
"    </em>",
"    Levels of total IgE increase during exacerbations of ABPA, and fall with successful therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link&amp;anchor=H9#H9\">",
"     \"Allergic bronchopulmonary aspergillosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3927919\">",
"    <span class=\"h2\">",
"     Allergic rhinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic rhinitis is associated with positive skin-test reactions (or allergen-specific IgE antibodies), but is independent of total IgE levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/39\">",
"     39",
"    </a>",
"    ]. Measurement of total IgE has low sensitivity (44 percent) for identification of patients with current allergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/40\">",
"     40",
"    </a>",
"    ]. In patients with perennial allergic rhinitis, total IgE levels did not correlate with either skin test reactivity or in vitro specific IgE testing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, a normal IgE level does not rule out allergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/42\">",
"     42",
"    </a>",
"    ]. The diagnosis of allergic rhinitis, seasonal or perennial, requires a suggestive history and physical exam and the demonstration of specific IgE to clinically-relevant aeroallergens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5310872\">",
"    <span class=\"h2\">",
"     Atopic dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even though it is called atopic dermatitis (AD), about 30 percent of patients are nonatopic, as determined by the absence of other allergic diseases, negative skin tests for common inhalant and food allergens, and normal total serum IgE levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/44\">",
"     44",
"    </a>",
"    ]. The importance of allergic triggers remains controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated total IgE levels can be demonstrated in 80 to 85 percent of patients with AD, although the precise relationship between the elevated IgE levels and disease pathogenesis is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/45\">",
"     45",
"    </a>",
"    ]. Some individuals have extremely high total IgE levels. Children with very high IgE (ie, &gt;10,000",
"    <span class=\"nowrap\">",
"     kU/L)",
"    </span>",
"    are at greater risk for severe AD, sensitization to food and inhaled allergens, and anaphylaxis, compared to children with lesser elevations (ie, 1000 to 4000",
"    <span class=\"nowrap\">",
"     kU/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with AD, the rate of sensitization to foods ranges from 30 to 80 percent, depending upon the population studied, although the actual rate of confirmed food allergy is much lower. The diagnosis of food allergy in patients with atopic dermatitis is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link&amp;anchor=H3#H3\">",
"     \"Role of allergy in atopic dermatitis (eczema)\", section on 'Allergen sensitization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3930204\">",
"    <span class=\"h3\">",
"     Food allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of food-specific IgE is predominantly useful for the evaluation of immediate allergic reactions, such as those that cause hives, wheezing, or anaphylaxis. Foods are also associated with other types of adverse reactions including celiac sprue (gluten sensitivity) and lactose intolerance, neither of which are IgE-mediated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations of food allergy: An overview\", section on 'Non-IgE mediated reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gold standard testing for food allergy is the double blind placebo-controlled oral challenge. This can be a labor intensive procedure with potential severe allergic reactions resulting from testing. Therefore, alternatives such as prick skin testing and in vitro food-specific IgE testing have been used as a substitute. Total IgE levels should not be used to make a diagnosis of food allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5310880\">",
"    <span class=\"h2\">",
"     Venom allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have experienced a systemic allergic reaction to a stinging insect (ie, bee, wasp, etc) or fire ants, or select patients with severe large local reactions to insect stings, should be evaluated for venom allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/48\">",
"     48",
"    </a>",
"    ]. Skin testing is the preferred method of diagnosing venom allergy. If initial testing is negative, in vitro testing for venom-specific IgE can be performed, or skin testing can be repeated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of total IgE has no role in the diagnosis of venom allergy. Patients with confirmed venom allergy should be offered venom immunotherapy, which is highly effective at reducing the risk of reactions to subsequent stings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14824?source=see_link\">",
"     \"Diagnosis of Hymenoptera venom allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5310888\">",
"    <span class=\"h2\">",
"     Drug allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a history suggestive of an immediate hypersensitivity allergic reaction, skin testing can be helpful to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/50\">",
"     50",
"    </a>",
"    ]. Penicillin is the only drug with validated testing available, although skin testing is performed with other medications as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H23#H23\">",
"     \"An approach to the patient with drug allergy\", section on 'Testing for immediate reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In vitro testing for drug-specific IgE is",
"    <strong>",
"     not",
"    </strong>",
"    generally useful, because its sensitivity is inferior to skin testing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/51\">",
"     51",
"    </a>",
"    ]. Total serum IgE is of no value in the evaluation of drug allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15831696\">",
"    <span class=\"h1\">",
"     RATIO OF ALLERGEN-SPECIFIC IgE TO TOTAL IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ratio of allergen-specific IgE to total IgE has been termed the &ldquo;specific activity&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/52\">",
"     52",
"    </a>",
"    ]. Its utility has been examined in the diagnosis of several allergic disorders, and in predicting individuals&rsquo; responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    therapy. One study found that, in the diagnosis of food allergy, the specific activity was no more useful than allergen-specific IgE alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/53\">",
"     53",
"    </a>",
"    ]. However, in the treatment of asthma with omalizumab, a specific activity greater than 3 to 4 percent was predictive of a reduced response to omalizumab therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30056/abstract/54\">",
"     54",
"    </a>",
"    ]. At present, the ratio of allergen-specific IgE to total IgE remains largely a research tool and overall clinical usefulness has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5310904\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergen-specific IgE production is a fundamental component of the pathogenesis of allergic disease. However, the measurement of total IgE and allergen-specific IgE has variable utility in the diagnosis and management of allergic disorders. (See",
"      <a class=\"local\" href=\"#H5310808\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atopy refers to the genetic predilection to produce allergen-specific IgE. Sensitization refers to the presence of allergen-specific IgE, in the absence of clinical disease. Individuals are considered to have clinically significant allergy or allergic disease when they have both allergen-specific IgE",
"      <strong>",
"       and",
"      </strong>",
"      develop symptoms upon exposure to that allergen. (See",
"      <a class=\"local\" href=\"#H1366636\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated total IgE is seen with some allergic disorders, as well as several nonallergic diseases (",
"      <a class=\"graphic graphic_table graphicRef83457 \" href=\"UTD.htm?29/49/30492\">",
"       table 1",
"      </a>",
"      ). Many patients (although not all) with allergic disorders have elevated levels of total IgE; however, there is no specific cutoff value that discriminates patients with allergic disease from those without, and there is considerable overlap. (See",
"      <a class=\"local\" href=\"#H25256003\">",
"       'Relationships between total IgE levels and allergic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated total IgE is associated with an increased risk of allergic disease, although there is significant overlap between affected individuals and normals, such that the measurement is most useful in the context of population studies, rather than in the diagnosis or management of an individual. Allergen-specific IgE is usually detectable several years before a person becomes reactive to that allergen, although only a subset of sensitized people will ever develop symptoms. (See",
"      <a class=\"local\" href=\"#H1128141\">",
"       'Utility in predicting the development of allergic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of total and allergen-specific IgE levels in pathogenesis and diagnosis differs among the leading allergic disorders. Asthma correlates with increased total IgE levels, regardless of atopic status. Allergic rhinitis is associated with allergen-specific IgE antibodies, although not with total IgE levels. Patients with atopic dermatitis may have very elevated levels of total IgE, although only a minority of patients (mostly children with severe AD) has clinically-apparent allergic reactions to food. (See",
"      <a class=\"local\" href=\"#H1366692\">",
"       'The role of IgE in specific disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/1\">",
"      Borish L. Allergic rhinitis: systemic inflammation and implications for management. J Allergy Clin Immunol 2003; 112:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/2\">",
"      Salo PM, Calatroni A, Gergen PJ, et al. Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2011; 127:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/3\">",
"      Nicolaou N, Poorafshar M, Murray C, et al. Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. J Allergy Clin Immunol 2010; 125:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/4\">",
"      Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res 2011; 3:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/5\">",
"      Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 2010; 105:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/6\">",
"      Ker J, Hartert TV. The atopic march: what's the evidence? Ann Allergy Asthma Immunol 2009; 103:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/7\">",
"      von Kobyletzki LB, Bornehag CG, Hasselgren M, et al. Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort. BMC Dermatol 2012; 12:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/8\">",
"      Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2004; 93:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/9\">",
"      Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2010; 125:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/10\">",
"      Klink M, Cline MG, Halonen M, Burrows B. Problems in defining normal limits for serum IgE. J Allergy Clin Immunol 1990; 85:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/11\">",
"      Omenaas E, Bakke P, Elsayed S, et al. Total and specific serum IgE levels in adults: relationship to sex, age and environmental factors. Clin Exp Allergy 1994; 24:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/12\">",
"      Wittig HJ, Belloit J, De Fillippi I, Royal G. Age-related serum immunoglobulin E levels in healthy subjects and in patients with allergic disease. J Allergy Clin Immunol 1980; 66:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/13\">",
"      Marsh DG, Bias WB, Ishizaka K. Genetic control of basal serum immunoglobulin E level and its effect on specific reaginic sensitivity. Proc Natl Acad Sci U S A 1974; 71:3588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/14\">",
"      B&oslash;nnelykke K, Pipper CB, Bisgaard H. Transfer of maternal IgE can be a common cause of increased IgE levels in cord blood. J Allergy Clin Immunol 2010; 126:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/15\">",
"      Kaan A, Dimich-Ward H, Manfreda J, et al. Cord blood IgE: its determinants and prediction of development of asthma and other allergic disorders at 12 months. Ann Allergy Asthma Immunol 2000; 84:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/16\">",
"      Wen HJ, Wang YJ, Lin YC, et al. Prediction of atopic dermatitis in 2-yr-old children by cord blood IgE, genetic polymorphisms in cytokine genes, and maternal mentality during pregnancy. Pediatr Allergy Immunol 2011; 22:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/17\">",
"      Ferguson A, Dimich-Ward H, Becker A, et al. Elevated cord blood IgE is associated with recurrent wheeze and atopy at 7 yrs in a high risk cohort. Pediatr Allergy Immunol 2009; 20:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/18\">",
"      Pesonen M, Kallio MJ, Siimes MA, et al. Cord serum immunoglobulin E as a risk factor for allergic symptoms and sensitization in children and young adults. Pediatr Allergy Immunol 2009; 20:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/19\">",
"      Shah PS, Wegienka G, Havstad S, et al. The relationship between cord blood immunoglobulin E levels and allergy-related outcomes in young adults. Ann Allergy Asthma Immunol 2011; 106:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/20\">",
"      Sherrill DL, Stein R, Halonen M, et al. Total serum IgE and its association with asthma symptoms and allergic sensitization among children. J Allergy Clin Immunol 1999; 104:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/21\">",
"      Hagy GW, Settipane GA. Risk factors for developing asthma and allergic rhinitis. A 7-year follow-up study of college students. J Allergy Clin Immunol 1976; 58:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/22\">",
"      Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994; 15:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/23\">",
"      Kartasamita CB, Rosmayudi O, Demedts M. Total serum IgE and eosinophil count in children with and without a history of asthma, wheezing, or atopy in an urban community in Indonesia. The Respiratory Disease Working Group. J Allergy Clin Immunol 1994; 94:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/24\">",
"      Sunyer J, Ant&oacute; JM, Castellsagu&eacute; J, et al. Total serum IgE is associated with asthma independently of specific IgE levels. The Spanish Group of the European Study of Asthma. Eur Respir J 1996; 9:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/25\">",
"      Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. Eur Respir J 2000; 16:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/26\">",
"      Gergen PJ, Arbes SJ Jr, Calatroni A, et al. Total IgE levels and asthma prevalence in the US population: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2009; 124:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/27\">",
"      Rajakulasingam K, Till S, Ying S, et al. Increased expression of high affinity IgE (FcepsilonRI) receptor-alpha chain mRNA and protein-bearing eosinophils in human allergen-induced atopic asthma. Am J Respir Crit Care Med 1998; 158:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/28\">",
"      Humbert M, Grant JA, Taborda-Barata L, et al. High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med 1996; 153:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/29\">",
"      den Otter I, Silva LF, Carvalho AL, et al. High-affinity immunoglobulin E receptor expression is increased in large and small airways in fatal asthma. Clin Exp Allergy 2010; 40:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/30\">",
"      Zhou J, Zhou Y, Lin LH, et al. Association of polymorphisms in the promoter region of FCER1A gene with atopic dermatitis, chronic uticaria, asthma, and serum immunoglobulin E levels in a Han Chinese population. Hum Immunol 2012; 73:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/31\">",
"      Anupama N, Vishnu Sharma M, Nagaraja HS, Ramesh Bhat M. The serum immunoglobulin E level reflects the severity of bronchial asthma. Thai Journal of Physiological Sciences 2005; 18:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/32\">",
"      Wood RA, Phipatanakul W, Hamilton RG, Eggleston PA. A comparison of skin prick tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy. J Allergy Clin Immunol 1999; 103:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/33\">",
"      Sunyer J, Ant&oacute; JM, Sabri&agrave; J, et al. Relationship between serum IgE and airway responsiveness in adults with asthma. J Allergy Clin Immunol 1995; 95:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/34\">",
"      Sears MR, Burrows B, Flannery EM, et al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/35\">",
"      Burrows B, Sears MR, Flannery EM, et al. Relations of bronchial responsiveness to allergy skin test reactivity, lung function, respiratory symptoms, and diagnoses in thirteen-year-old New Zealand children. J Allergy Clin Immunol 1995; 95:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/36\">",
"      Sherrill DL, Halonen M, Burrows B. Relationships between total serum IgE, atopy, and smoking: a twenty-year follow-up analysis. J Allergy Clin Immunol 1994; 94:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/37\">",
"      Sherrill DL, Lebowitz MD, Halonen M, et al. Longitudinal evaluation of the association between pulmonary function and total serum IgE. Am J Respir Crit Care Med 1995; 152:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/38\">",
"      Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/39\">",
"      Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/40\">",
"      Tschopp JM, Sistek D, Schindler C, et al. Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults. Allergy 1998; 53:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/41\">",
"      Ba&ntilde;uelos Arias Adel C, Monta&ntilde;o Vel&aacute;zquez BB, Campillo Navarrete MR, et al. [Skin tests, serum specific IgE and total IgE in the diagnosis of patients with perennial allergic rhinitis]. Rev Alerg Mex 2003; 50:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/42\">",
"      Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol 2008; 100:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/43\">",
"      Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/44\">",
"      Schmid-Grendelmeier P, Simon D, Simon HU, et al. Epidemiology, clinical features, and immunology of the \"intrinsic\" (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001; 56:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/45\">",
"      Liu FT, Goodarzi H, Chen HY. IgE, mast cells, and eosinophils in atopic dermatitis. Clin Rev Allergy Immunol 2011; 41:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/46\">",
"      Eigenmann PA, Sicherer SH, Borkowski TA, et al. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998; 101:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/47\">",
"      NIAID-Sponsored Expert Panel, Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 126:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/48\">",
"      Golden DB, Moffitt J, Nicklas RA, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011; 127:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/49\">",
"      Golden DB, Kagey-Sobotka A, Norman PS, et al. Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol 2001; 107:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/50\">",
"      Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/51\">",
"      Macy E, Goldberg B, Poon KY. Use of commercial anti-penicillin IgE fluorometric enzyme immunoassays to diagnose penicillin allergy. Ann Allergy Asthma Immunol 2010; 105:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/52\">",
"      Hamilton RG, MacGlashan DW Jr, Saini SS. IgE antibody-specific activity in human allergic disease. Immunol Res 2010; 47:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/53\">",
"      Mehl A, Verstege A, Staden U, et al. Utility of the ratio of food-specific IgE/total IgE in predicting symptomatic food allergy in children. Allergy 2005; 60:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30056/abstract/54\">",
"      Johansson SG, Nopp A, Oman H, et al. The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment. Allergy 2009; 64:1472.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83038 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-2BDF7BB03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30056=[""].join("\n");
var outline_f29_22_30056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5310904\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5310808\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1366636\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1366629\">",
"      Atopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1366655\">",
"      Sensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1366662\">",
"      Allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4432104\">",
"      The atopic march",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25256003\">",
"      RELATIONSHIPS BETWEEN TOTAL IgE LEVELS AND ALLERGIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1127469\">",
"      Elevated total serum IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15831609\">",
"      Low or normal levels of total serum IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1128141\">",
"      Utility in predicting the development of allergic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1128173\">",
"      - Cord blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1126963\">",
"      - Childhood IgE levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1127398\">",
"      - Timeline of sensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1366692\">",
"      THE ROLE OF IgE IN SPECIFIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5310840\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5310848\">",
"      - Lung function correlates with IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5310864\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3927919\">",
"      Allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5310872\">",
"      Atopic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3930204\">",
"      - Food allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5310880\">",
"      Venom allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5310888\">",
"      Drug allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15831696\">",
"      RATIO OF ALLERGEN-SPECIFIC IgE TO TOTAL IgE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5310904\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/83038\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/83038|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/30/42469\" title=\"figure 1\">",
"      Allergen sensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/83038|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/49/30492\" title=\"table 1\">",
"      Diff dx elevated IgE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=related_link\">",
"      An approach to the patient with drug allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=related_link\">",
"      Antigen presenting cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=related_link\">",
"      Chronic nonallergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14824?source=related_link\">",
"      Diagnosis of Hymenoptera venom allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=related_link\">",
"      Mast cell derived mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=related_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=related_link\">",
"      T helper subsets: Differentiation and role in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=related_link\">",
"      The biology of IgE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_22_30057="Neurologic manifestations of hyperthyroidism and Graves' disease";
var content_f29_22_30057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic manifestations of hyperthyroidism and Graves' disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/22/30057/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30057/contributors\">",
"     Devon I Rubin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/22/30057/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30057/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30057/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/22/30057/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30057/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/22/30057/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthyroidism is a common medical condition in the general population. The most common cause of hyperthyroidism is Graves' disease, but elevated thyroid hormone levels may occur due to thyroiditis, multinodular goiter, toxic thyroid nodule, or excess thyroid hormone supplementation.",
"   </p>",
"   <p>",
"    Common systemic features of hyperthyroidism include palpitations, heat intolerance, and weight loss. A number of central and peripheral nervous system manifestations may also occur in patients with hyperthyroidism (",
"    <a class=\"graphic graphic_table graphicRef60148 \" href=\"UTD.htm?13/62/14316\">",
"     table 1",
"    </a>",
"    ). In many cases, the neurologic manifestations occur in conjunction with the systemic features of the disease, but these may be the presenting symptom in some patients.",
"   </p>",
"   <p>",
"    This topic reviews the neurologic manifestations of hyperthyroidism. Other clinical features of hyperthyroidism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"    </a>",
"    .) The diagnosis of hyperthyroidism is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COGNITIVE DYSFUNCTION AND SEIZURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive impairment is common in hyperthyroidism and may present as one or more different syndromes. In one review of elderly patients with hyperthyroidism, dementia and confusion was found in 33 percent and 18 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/1\">",
"     1",
"    </a>",
"    ]. Studies in younger individuals with newly-diagnosed or induced hyperthyroidism have found lower cognitive scores compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also inconclusive evidence suggesting that mild hyperthyroidism may be a risk factor for dementia. Case control and population-based cohort studies have had conflicting results, with some finding a positive association between low thyrotropin (TSH) levels and others not [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Low TSH in this setting may represent subclinical hyperthyroidism, but may instead be associated with hypothyroidism if it is the result of decreased thyrotropin-releasing hormone production, itself a consequence of neurodegeneration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36585?source=see_link&amp;anchor=H8#H8\">",
"     \"Neurologic manifestations of hypothyroidism\", section on 'Alzheimer disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with thyrotoxicosis may experience behavioral and personality changes, such as psychosis, agitation, and depression. Less overt manifestations that are more common in less severe thyrotoxicosis include anxiety, restlessness, irritability, and emotional lability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/10\">",
"     10",
"    </a>",
"    ]. Insomnia is also common. Elderly patients may have a less activated presentation with depression and lethargy, so-called apathetic thyrotoxicosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/1\">",
"     1",
"    </a>",
"    ]. These behavioral manifestations are accompanied by cognitive impairments, particularly impaired concentration, confusion, poor orientation and immediate recall, amnesia, and constructional difficulties.",
"   </p>",
"   <p>",
"    Seizures may accompany the encephalopathy of acute thyrotoxicosis and occasionally are the presenting clinical feature [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/11\">",
"     11",
"    </a>",
"    ]. They may be focal or generalized [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Tremor and hyperreflexia with other pyramidal tract signs are also common features of the neurologic examination in thyrotoxicosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Tremor'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Motor neuron disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The presentation of cognitive dysfunction in hyperthyroidism is usually subacute; however, a more protracted course similar to a degenerative dementia has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/16\">",
"     16",
"    </a>",
"    ]. In severe thyrotoxicosis, a condition frequently referred to as thyroid storm, the neurologic presentation is more fulminant, progressing if untreated through an agitated delirium to somnolence and ultimately to coma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/17\">",
"     17",
"    </a>",
"    ]. In many of these cases there is an underlying stressor, such as sepsis, trauma, or a recent surgical procedure. Seizures are more prominent in this setting and may include status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/12,13,18\">",
"     12,13,18",
"    </a>",
"    ]. Other clinical features of thyroid storm, such as tachycardia, fever, and gastrointestinal symptoms, are commonly present (",
"    <a class=\"graphic graphic_table graphicRef60908 \" href=\"UTD.htm?34/24/35213\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no reports of abnormalities on magnetic resonance imaging (MRI) or computed tomography (CT) neuroimaging studies. However, in one patient, single photon emission CT (SPECT) demonstrated diffusely reduced cerebral uptake with an accentuation in the temporoparietal regions bilaterally, which improved following resolution of the hyperthyroid state [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonspecific electroencephalography (EEG) abnormalities have been reported in 43 percent of patients with hyperthyroid encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/19\">",
"     19",
"    </a>",
"    ]. EEG may demonstrate diffuse slowing, bitemporal sharp waves, polyspike and slow wave discharges, or may be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. In addition, an unusually high voltage with prolonged photic response and triphasic waves have been described in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/11,20\">",
"     11,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of cognitive and behavioral dysfunction in hyperthyroidism is not known. Improvement of some clinical features (attention and concentration) with beta-blocker therapy suggests a role for a hyperthyroid-induced hyperactive adrenergic system, possibly disrupting the adrenergic pathways between the locus ceruleus and frontal lobe that subserve attention and vigilance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/16\">",
"     16",
"    </a>",
"    ]. Others propose that hyperthyroidism may produce oxidative stress, producing neuronal injury and hastening a presentation of degenerative or vascular dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of seizures in thyrotoxicosis is also not known. Animal studies have demonstrated that exogenous administration of thyroxine lowers the seizure threshold. Elevated thyroxine levels have also been associated with precipitating seizures in two patients with previously well-controlled juvenile myoclonic epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hyperthyroidism typically leads to improvement in cognitive and behavioral impairments. Agitation, inattention, and frontal lobe impairment may improve more rapidly than other cognitive functions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/1\">",
"     1",
"    </a>",
"    ]. However, cognitive dysfunction may persist despite a return to a euthyroid state.",
"   </p>",
"   <p>",
"    Seizures in thyrotoxicosis are ultimately treated by thyroid lowering; however, antiepileptic drugs are often used as a temporizing measure until euthyroidism is achieved. Recurrence of both generalized tonic-clonic seizures and encephalopathy coinciding with recurrence of the hyperthyroid state has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/14\">",
"     14",
"    </a>",
"    ]. EEG may normalize with treatment, although persistence of EEG abnormalities despite a return to a euthyroid state has also been described in isolated cases, without clear prognostic implications regarding either seizure recurrence or persistence of the encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MOVEMENT DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tremor is common in patients with thyrotoxicosis. In one small series of patients with a new diagnosis of hyperthyroidism, tremor was observed in 76 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/23\">",
"     23",
"    </a>",
"    ]. The tremor is typically high frequency and low amplitude, primarily seen with action, and can involve the face and head as well as the extremities. It is more usual for the tremor to be incidental to other manifestations of hyperthyroidism; however, at times a disabling tremor is the presenting complaint.",
"   </p>",
"   <p>",
"    The characteristics of the tremor, which resemble an exaggerated physiologic tremor, and its responsiveness to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , suggest that the pathogenesis is mediated by a heightened beta-adrenergic state [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of tremor\", section on 'Physiologic tremor'",
"    </a>",
"    .) Others have suggested a role for increased metabolism of dopamine in the etiology of hyperthyroid tremor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chorea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorea is a rare complication of hyperthyroidism, occurring in less than 2 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/26\">",
"     26",
"    </a>",
"    ]. Chorea usually occurs in the context of other features of hyperthyroidism, but it may be a presenting symptom of a thyrotoxic state. In most cases, the onset of chorea is gradual, but a sudden onset of unilateral chorea has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/27\">",
"     27",
"    </a>",
"    ]. Chorea may be unilateral, bilateral, or multifocal and involves the extremities predominantly and less often the trunk or facial muscles. It may be continuous or occur in paroxysms that are spontaneous or precipitated by sudden movements [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) and single photon emission computed tomography (SPECT) studies are normal, with no significant structural abnormality or abnormal cerebral perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occurring in nonautoimmune thyroid disease as well as Graves' disease, chorea is believed to represent a direct effect of thyrotoxicosis on the central nervous system. Hyperthyroidism may induce a reversible functional alteration in the dopamine turnover or receptor site response to dopamine in the corpus striatum. Studies have shown a reduction in the production and turnover of the level of homovanillic acid (HVA), a metabolite of dopamine, in the cerebrospinal fluid in hyperthyroid patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/31\">",
"     31",
"    </a>",
"    ]. This would be an expected result of an increased sensitivity of dopamine receptors and a resulting decrease in dopamine turnover.",
"   </p>",
"   <p>",
"    Chorea may improve or resolve with correction of thyroid hormone levels. In some patients, this occurs rapidly; in others, it may be delayed for several weeks or more after achieving a euthyroid state [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/32\">",
"     32",
"    </a>",
"    ]. Recurrence of chorea coincident with an increase in thyroid hormone levels has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/26,33\">",
"     26,33",
"    </a>",
"    ]. Persistence of the chorea, even for decades following treatment of hyperthyroidism, has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to thyroid lowering, treatment of disabling or persistent chorea consists of dopamine antagonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    . Some patients may respond to beta-blockers or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"     reserpine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link\">",
"     \"Hyperkinetic movement disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus occurs rarely in hyperthyroidism. Isolated cases of unusual myoclonus affecting the trunk muscles or the platysma have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ballism accompanying chorea has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     STROKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic cerebrovascular disease is a rare complication of hyperthyroidism. In a prospective cohort study, 3176 patients aged 18 to 44 years with hyperthyroidism were followed for five years after the initial diagnosis; the cumulative incidence of ischemic stroke was 1.0 percent compared to 0.6 percent in a control group (HR = 1.44) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, except for cardiogenic embolism in the setting of hyperthyroid-induced atrial fibrillation (AF), associations of hyperthyroidism with other stroke subtypes remain speculative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cardiogenic embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral infarction related to hyperthyroidism most commonly occurs as a result of a cardiogenic embolism in patients with hyperthyroid-induced AF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/38\">",
"     38",
"    </a>",
"    ]. AF occurs in 10 to 15 percent of individuals with hyperthyroidism and can be the presenting symptom. AF is more common in men than women, and its prevalence increases with age. Subclinical as well as overt hyperthyroidism is a risk factor for AF. However, thyrotoxicosis causes a small percentage (&lt;1 percent) of AF cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\", section on 'Cardiovascular'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies suggest that stroke in the setting of thyrotoxic AF is more frequent than in nonthyrotoxic AF, but others find no difference in arterial embolism rates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H26#H26\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Patients with hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anticoagulation is recommended for secondary prevention of cerebrovascular events in the setting of thyrotoxic AF. Anticoagulation is more controversial for primary prevention. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=see_link&amp;anchor=H12#H12\">",
"     \"Cardiovascular effects of hyperthyroidism\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cerebral venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral venous sinus thrombosis (CVT) is a rare thrombotic cerebrovascular disorder with high morbidity and mortality, often occurring in association with dehydration, central nervous system infection, or hypercoagulable states; about 25 percent of CVT are idiopathic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/38\">",
"     38",
"    </a>",
"    ]. An association between CVT and hyperthyroidism has been suggested by reports of several patients who developed CVT simultaneously with a thyrotoxic state or Graves' disease and who had no other risk factors for CVT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. The number of reported cases is reported to be higher than that expected by chance alone, given the low incidence of each condition [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/38,42\">",
"     38,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of CVT in hyperthyroidism may be related to an induced hypercoagulable state, possibly from increased Factor VIII clotting activity, documented in at least two cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/38,42\">",
"     38,42",
"    </a>",
"    ]. In another patient, elevated plasma fibrinogen and decreased protein C activity may have contributed to a thrombotic state [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/44\">",
"     44",
"    </a>",
"    ]. Other possible contributors include altered hemodynamics or dehydration induced by thyrotoxicosis, and venous stasis due to compressive effects of a thyroid goiter on cervical veins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/38,43\">",
"     38,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of CVT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone may also directly affect vascular smooth muscle and endothelium and alter vascular reactivity. These changes may predispose patients to cerebrovascular complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two cases of fatal stroke and bilateral carotid artery dissection have been reported in individuals with poorly-controlled Graves' disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/45\">",
"       45",
"      </a>",
"      ]. Pathologic examination of the carotid arteries revealed a segmental mediolytic arteriopathy, an idiopathic noninflammatory vasculopathy that predisposes to dissection and aneurysm formation in cerebral and systemic blood vessels. A small case control study found that autoimmune thyroid disease (both autoimmune thyroiditis as well as Graves' disease) was associated with spontaneous carotid dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple intracranial stenoses, similar to that seen in moyamoya disease, has been described in several patients with Graves' disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/38,47\">",
"       38,47",
"      </a>",
"      ]. Predominantly female, these patients had symptoms at a young age (mean 31 years). Clinical manifestations included transient ischemic attack and intracerebral hemorrhage. Proposed pathophysiologic mechanisms include an autoimmune process affecting the cerebral arteries or a vasculopathy produced by chronic thyrotoxic-activation of the sympathetic nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=see_link\">",
"       \"Moyamoya disease: Etiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coincident autoimmune disorders may contribute to an increased risk of antiphospholipid syndrome, giant cell arteritis, and Takayasu arteritis in patients with hyperthyroidism due to Graves' disease. However, as such cases are largely individually reported, an association between these disorders and Graves' disease is unproven [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/49-53\">",
"       49-53",
"      </a>",
"      ]. One case control study did not find an association between giant cell arteritis and hyperthyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PERIPHERAL NERVOUS SYSTEM MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Myasthenia gravis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally recognized that there is an association between myasthenia gravis and hyperthyroidism, particularly Graves' disease. The reported prevalence of hyperthyroidism in series of patients with myasthenia gravis (MG) ranges between 2 to 17 percent, compared with a 1 in 10,000 prevalence in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between the two disorders is likely a shared autoimmune pathogenesis. Some, but not all, case series and case control studies have reported higher prevalence of antithyroid antibodies among patients with MG [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A closer association between the two disorders is also suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 44 of 51 of patients with MG and hyperthyroidism in one series, thyrotoxicosis occurred simultaneously with or prior to the development of MG [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/55\">",
"       55",
"      </a>",
"      ]. More than half of the patients demonstrated parallel disease activity with worsening of both diseases over a similar period of time.",
"     </li>",
"     <li>",
"      The clinical manifestations of MG patients may be influenced by comorbid autoimmune thyroid disease. In one study, MG associated with autoimmune thyroid disease was found to have a higher proportion of ocular MG compared with patients with MG without thyroid disease (41 versus 21 percent), as well as a lower frequency of thymic disease (27 versus 60 percent) and acetylcholine receptor antibodies (36 versus 57 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/59\">",
"       59",
"      </a>",
"      ]. The association between ocular MG and Graves' disease may reflect immunological cross-reactivity against common autoimmune targets in the eye muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/60\">",
"       60",
"      </a>",
"      ]. However, in another case series, generalized MG predominated, in two-thirds of 56 patients with thyrotoxicosis and MG [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There may also be common genetic susceptibility in the two disorders. In one case series, all five patients with both MG and Graves' disease had in common the HLA antigen type, HLA-DQ3 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ocular MG and Graves' ophthalmopathy have overlapping symptoms but can generally be distinguished. Ptosis and orbicularis oculi weakness suggest ocular MG, while proptosis, lid retraction, lid lag, periorbital edema, and restricted eye movement with forced ductions suggest Graves' ophthalmopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=see_link&amp;anchor=H8#H8\">",
"     \"Ocular myasthenia gravis\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment and prognosis of MG is similar in patients with and without hyperthyroidism and consists of acetylcholinesterase inhibitors, immunosuppressive therapy, and thymectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/56,62\">",
"     56,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link\">",
"     \"Treatment of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of hyperthyroidism alone does not usually affect MG, although both improvement and worsening of MG symptoms with thyroid lowering have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. When the thyroid disorder is due to autoimmunity, immunosuppressive medications may lead to remission of both disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/55\">",
"     55",
"    </a>",
"    ]. Thymectomy appears to have no influence on hyperthyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Thyrotoxic periodic paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyrotoxic periodic paralysis (PP) represents an acquired form of hypokalemic PP, in which attacks of generalized weakness occur, often precipitated by rest after strenuous exercise or a high-carbohydrate load. Thyrotoxic PP is more prevalent in Asians than in non-Asians and in males than in females. Any cause of hyperthyroidism can be associated with thyrotoxic PP.",
"   </p>",
"   <p>",
"    This disorder is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=see_link\">",
"     \"Thyrotoxic periodic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle weakness with or without atrophy and myalgias occurs in 60 to 80 percent of patients with untreated hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/23,65,66\">",
"     23,65,66",
"    </a>",
"    ]. However, it is uncommon for a patient with hyperthyroidism to present with muscle weakness as the chief complaint. Patients with hyperthyroidism tend to develop muscle involvement more frequently after the age of 40. The likelihood of developing weakness, but not its degree, is correlated with the duration of the hyperthyroid state.",
"   </p>",
"   <p>",
"    The pathogenesis of myopathy in thyrotoxicosis is unknown. The rapid response to thyroid-lowering treatment, at least in some patients, and a partial improvement with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    suggests that the muscle dysfunction is at least partly physiologic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/23,67\">",
"     23,67",
"    </a>",
"    ]. Contributing features may include increased cellular metabolism and energy utilization, increased catabolism and protein degradation, and inefficient energy utilization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. A significant reduction in muscle",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    was identified in patients with hyperthyroid myopathy compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/72\">",
"     72",
"    </a>",
"    ], and it is possible that this reduction contributes to myopathy.",
"   </p>",
"   <p>",
"    As with the underlying thyroid disorder, the clinical presentation of myopathy may be acute or chronic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute thyrotoxic myopathy may present with more severe proximal and distal weakness, and rarely with bulbar or respiratory muscle involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/73\">",
"       73",
"      </a>",
"      ]. Rhabdomyolysis has been described in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/74-76\">",
"       74-76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic thyrotoxic myopathy is more common. About two-thirds of patients with hyperthyroid myopathy report proximal weakness that usually begins several weeks to several months after the onset of hyperthyroidism. Hip flexors and quadriceps are predominantly affected [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/23\">",
"       23",
"      </a>",
"      ]. The remainder usually has distal as well as proximal muscle involvement, although one series reported predominantly distal extremity weakness in 20 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/77\">",
"       77",
"      </a>",
"      ]. The myopathy may be associated with myalgias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both presentations, muscle atrophy is usually absent. However, several cases with atrophy of shoulder muscles have been described. Isolated dysphagia has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/73,78\">",
"     73,78",
"    </a>",
"    ]. Deep tendon reflexes are usually normal or increased, an unusual finding in a myopathic disorder, with a shortened relaxation phase [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/23,77\">",
"     23,77",
"    </a>",
"    ]. Paresthesias, due to coexisting polyneuropathy may be present. Cramps are less common than with hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/23\">",
"     23",
"    </a>",
"    ]. Bulbar and respiratory muscle dysfunction occurs rarely [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/77,79\">",
"     77,79",
"    </a>",
"    ]. Weakness is sometimes the sole manifestation of the endocrinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/66,77\">",
"     66,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When a patient with hyperthyroidism presents with acute weakness or has prominent bulbar muscle involvement, myasthenia gravis is more likely than muscle disease and should be carefully ruled out in these settings. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Myasthenia gravis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Laboratory studies are unremarkable apart from abnormal thyroid function tests. Serum creatine kinase is generally normal, except in thyrotoxic crisis, but elevated aldolase occurs in approximately 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/23,77\">",
"     23,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electromyography (EMG) may be normal but sometimes demonstrates myopathic findings of increased polyphasic, low amplitude motor unit potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/66,77,80\">",
"     66,77,80",
"    </a>",
"    ]. One study found \"myopathic\" changes in only 10 percent of 21 patients, while 24 percent had \"neuropathic\" changes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/23\">",
"     23",
"    </a>",
"    ]. Spontaneous activity is atypical. Abnormal EMG has been described in hyperthyroid individuals without clinical weakness. Muscle biopsy is rarely performed, but may be normal or may show nonspecific findings. Rarely, inflammation occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of the hyperthyroid condition is usually sufficient to treat the myopathy. Symptoms may improve over a few to several months following return to euthyroid state [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/23,82\">",
"     23,82",
"    </a>",
"    ]. Adrenergic blocking agents may be of benefit as well [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sensory polyneuropathy may occur with hyperthyroidism. A symmetric distal sensory disturbance and reduced Achilles reflexes are the most common features. Electrodiagnostic testing with nerve conduction studies and EMG is abnormal in up to 24 percent of thyrotoxic patients and is usually consistent with an axonal pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/23,84-86\">",
"     23,84-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of hyperthyroidism with return to a euthyroid state leads to improvement of symptoms. In one small case series, resolution of sensory complaints occurred in all patients over a seven-month period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unusual neuropathic syndromes associated with hyperthyroidism include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term Basedow's paraplegia has been used to describe an acute development of severe leg weakness and areflexia, which occurs in the setting of severe thyrotoxicosis or thyroid storm [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/85,87\">",
"       85,87",
"      </a>",
"      ]. The arms are usually also weak, but are less severely affected. Patients recover with treatment of hyperthyroidism.",
"     </li>",
"     <li>",
"      Guillain-Barr&eacute; syndrome and chronic inflammatory demyelinating polyneuropathy have also been described in patients with hyperthyroidism, probably reflecting an underlying predisposition to autoimmune disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/88,89\">",
"       88,89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Carpal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;While hypothyroidism causes a small but significant proportion of cases of carpal tunnel syndrome (CTS), hyperthyroidism is an uncertain risk factor. In a prospective study of 150 patients with CTS, two patients were found with a past history of thyrotoxicosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prospective studies have identified CTS in 5 to 7 percent of patients with thyrotoxicosis, although other potential contributing factors, such as diabetes, were not excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. This seems only marginally increased over the prevalence in the general population of 3 to 5 percent. However, the simultaneous onset of CTS symptoms and thyrotoxicosis, and their remittance with treatment of hyperthyroidism, suggests a possible relationship. The pathophysiologic mechanism is not known.",
"   </p>",
"   <p>",
"    The symptoms of CTS in patients with hyperthyroidism are indistinguishable from those with idiopathic CTS, with sensory loss or paresthesias in the hand in the median nerve distribution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Motor neuron disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of an association between hyperthyroidism and motor neuron disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/93\">",
"     93",
"    </a>",
"    ]. However, clinical features in patients with thyrotoxicosis may include upper motor neuron signs related to pyramidal tract dysfunction as well as lower motor neuron signs related to a peripheral neuropathy, which may overlap with those of amyotrophic lateral sclerosis (ALS) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/84,85,94,95\">",
"     84,85,94,95",
"    </a>",
"    ]. In one case series, generalized hyperreflexia was seen in 38 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/23\">",
"     23",
"    </a>",
"    ]. In rare cases of thyrotoxicosis, there is also corticobulbar involvement with pseudobulbar speech [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/84\">",
"     84",
"    </a>",
"    ]. One literature review identified 19 reported cases of thyrotoxicosis with clinical features of upper and lower motor neuron involvement, similar to ALS; 16 of these patients improved with treatment of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Graves' ophthalmopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graves' ophthalmopathy, an autoimmune, inflammatory disease of the retroorbital tissues, occurs in 20 to 25 percent of patients with Graves' disease. Clinical symptoms include bilateral proptosis, restricted eye movements, and periorbital edema. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"     \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35239?source=see_link\">",
"     \"Treatment of Graves' orbitopathy (ophthalmopathy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of Graves' ophthalmopathy, patients may demonstrate other ophthalmic signs: widened palpebral fissures, infrequent blinking, and the appearance of lid retraction. These are believed to result from heightened sensitivity of receptors to sympathetic nervous system activity.",
"   </p>",
"   <p>",
"    An enlarged thyroid gland may compress the recurrent laryngeal nerve, producing vocal cord paralysis, dysphonia, and even respiratory stridor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30057/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. A Horner's syndrome may also result from compression of the sympathetic chain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic manifestations are common in patients with hyperthyroidism. These are diverse, affecting the central and peripheral nervous systems. Most represent direct or indirect effects of hyperthyroidism on the nervous system, while others (myasthenia gravis and Graves' ophthalmopathy) are related to autoimmune disease associated with Graves' disease. The most common of these conditions are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef60148 \" href=\"UTD.htm?13/62/14316\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/1\">",
"      Martin FI, Deam DR. Hyperthyroidism in elderly hospitalised patients. Clinical features and treatment outcomes. Med J Aust 1996; 164:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/2\">",
"      Wu T, Flowers JW, Tudiver F, et al. Subclinical thyroid disorders and cognitive performance among adolescents in the United States. BMC Pediatr 2006; 6:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/3\">",
"      Yudiarto FL, Muliadi L, Moeljanto D, Hartono B. Neuropsychological findings in hyperthyroid patients. Acta Med Indones 2006; 38:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/4\">",
"      Schlote B, Schaaf L, Schmidt R, et al. Mental and physical state in subclinical hyperthyroidism: investigations in a normal working population. Biol Psychiatry 1992; 32:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/5\">",
"      D&ouml;bert N, Hamscho N, Menzel C, et al. Subclinical hyperthyroidism in dementia and correlation of the metabolic index in FDG-PET. Acta Med Austriaca 2003; 30:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/6\">",
"      Kalmijn S, Mehta KM, Pols HA, et al. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf) 2000; 53:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/7\">",
"      van der Cammen TJ, Mattace-Raso F, van Harskamp F, de Jager MC. Lack of association between thyroid disorders and Alzheimer's disease in older persons: a cross-sectional observational study in a geriatric outpatient population. J Am Geriatr Soc 2003; 51:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/8\">",
"      van Osch LA, Hogervorst E, Combrinck M, Smith AD. Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease. Neurology 2004; 62:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/9\">",
"      de Jong FJ, den Heijer T, Visser TJ, et al. Thyroid hormones, dementia, and atrophy of the medial temporal lobe. J Clin Endocrinol Metab 2006; 91:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/10\">",
"      Stern RA, Robinson B, Thorner AR, et al. A survey study of neuropsychiatric complaints in patients with Graves' disease. J Neuropsychiatry Clin Neurosci 1996; 8:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/11\">",
"      Jabbari B, Huott AD. Seizures in thyrotoxicosis. Epilepsia 1980; 21:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/12\">",
"      Safe AF, Griffiths KD, Maxwell RT. Thyrotoxic crisis presenting as status epilepticus. Postgrad Med J 1990; 66:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/13\">",
"      Lee TG, Ha CK, Lim BH. Thyroid storm presenting as status epilepticus and stroke. Postgrad Med J 1997; 73:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/14\">",
"      Li Voon Chong JS, Lecky BR, Macfarlane IA. Recurrent encephalopathy and generalised seizures associated with relapses of thyrotoxicosis. Int J Clin Pract 2000; 54:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/15\">",
"      Newcomer J, Haire W, Hartman CR. Coma and thyrotoxicosis. Ann Neurol 1983; 14:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/16\">",
"      Fukui T, Hasegawa Y, Takenaka H. Hyperthyroid dementia: clinicoradiological findings and response to treatment. J Neurol Sci 2001; 184:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/17\">",
"      Trasciatti S, Prete C, Palummeri E, Foppiani L. Thyroid storm as precipitating factor in onset of coma in an elderly woman: case report and literature review. Aging Clin Exp Res 2004; 16:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/18\">",
"      Aiello DP, DuPlessis AJ, Pattishall EG 3rd, Kulin HE. Thyroid storm. Presenting with coma and seizures. In a 3-year-old girl. Clin Pediatr (Phila) 1989; 28:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/19\">",
"      SKANSE B, NYMAN GE. Thyrotoxicosis as a cause of cerebral dysrhythmia and convulsive seizures. Acta Endocrinol (Copenh) 1956; 22:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/20\">",
"      Primavera A, Brusa G, Novello P. Thyrotoxic encephalopathy and recurrent seizures. Eur Neurol 1990; 30:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/21\">",
"      Su YH, Izumi T, Kitsu M, Fukuyama Y. Seizure threshold in juvenile myoclonic epilepsy with Graves disease. Epilepsia 1993; 34:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/22\">",
"      Scott TF. Thyrotoxicosis and seizures. South Med J 1988; 81:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/23\">",
"      Duyff RF, Van den Bosch J, Laman DM, et al. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry 2000; 68:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/24\">",
"      Henderson JM, Portmann L, Van Melle G, et al. Propranolol as an adjunct therapy for hyperthyroid tremor. Eur Neurol 1997; 37:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/25\">",
"      Kim HT, Edwards MJ, Lakshmi Narsimhan R, Bhatia KP. Hyperthyroidism exaggerating parkinsonian tremor: a clinical lesson. Parkinsonism Relat Disord 2005; 11:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/26\">",
"      Risti�� AJ, Svetel M, Dragasevi�� N, et al. Bilateral chorea-ballism associated with hyperthyroidism. Mov Disord 2004; 19:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/27\">",
"      Baba M, Terada A, Hishida R, et al. Persistent hemichorea associated with thyrotoxicosis. Intern Med 1992; 31:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/28\">",
"      Fischbeck KH, Layzer RB. Paroxysmal choreoathetosis associated with thyrotosicosis. Ann Neurol 1979; 6:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/29\">",
"      Yen DJ, Shan DE, Lu SR. Hyperthyroidism presenting as recurrent short paroxysmal kinesigenic dyskinesia. Mov Disord 1998; 13:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/30\">",
"      Puri V, Chaudhry N. Paroxysmal kinesigenic dyskinesia manifestation of hyperthyroidism. Neurol India 2004; 52:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/31\">",
"      Klawans HL Jr, Shenker DM. Observations on the dopaminergic nature of hyperthyroid chorea. J Neural Transm 1972; 33:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/32\">",
"      Isaacs JD, Rakshi J, Baker R, et al. Chorea associated with thyroxine replacement therapy. Mov Disord 2005; 20:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/33\">",
"      Lucantoni C, Grottoli S, Moretti A. Chorea due to hyperthyroidism in old age. A case report. Acta Neurol (Napoli) 1994; 16:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/34\">",
"      Javaid A, Hilton DD. Persistent chorea as a manifestation of thyrotoxicosis. Postgrad Med J 1988; 64:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/35\">",
"      Teoh HL, Lim EC. Platysmal myoclonus in subclinical hyperthyroidism. Mov Disord 2005; 20:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/36\">",
"      Loh LM, Hum AY, Teoh HL, Lim EC. Graves' disease associated with spasmodic truncal flexion. Parkinsonism Relat Disord 2005; 11:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/37\">",
"      Sheu JJ, Kang JH, Lin HC, Lin HC. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke 2010; 41:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/38\">",
"      Squizzato A, Gerdes VE, Brandjes DP, et al. Thyroid diseases and cerebrovascular disease. Stroke 2005; 36:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/39\">",
"      Presti CF, Hart RG. Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J 1989; 117:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/40\">",
"      Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke 1988; 19:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/41\">",
"      Molloy E, Cahill M, O'Hare JA. Cerebral venous sinus thrombosis precipitated by Graves' disease and Factor V Leiden mutation. Ir Med J 2003; 96:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/42\">",
"      Verberne HJ, Fliers E, Prummel MF, et al. Thyrotoxicosis as a predisposing factor for cerebral venous thrombosis. Thyroid 2000; 10:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/43\">",
"      Siegert CE, Smelt AH, de Bruin TW. Superior sagittal sinus thrombosis and thyrotoxicosis. Possible association in two cases. Stroke 1995; 26:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/44\">",
"      Ra CS, Lui CC, Liang CL, et al. Superior sagittal sinus thrombosis induced by thyrotoxicosis. Case report. J Neurosurg 2001; 94:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/45\">",
"      Campos CR, Basso M, Evaristo EF, et al. Bilateral carotid artery dissection with thyrotoxicosis. Neurology 2004; 63:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/46\">",
"      Pezzini A, Del Zotto E, Mazziotti G, et al. Thyroid autoimmunity and spontaneous cervical artery dissection. Stroke 2006; 37:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/47\">",
"      Nakamura K, Yanaka K, Ihara S, Nose T. Multiple intracranial arterial stenoses around the circle of Willis in association with Graves' disease: report of two cases. Neurosurgery 2003; 53:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/48\">",
"      Tendler BE, Shoukri K, Malchoff C, et al. Concurrence of Graves' disease and dysplastic cerebral blood vessels of the moyamoya variety. Thyroid 1997; 7:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/49\">",
"      Marongiu F, Conti M, Murtas ML, et al. Anticardiolipin antibodies in Grave's disease: relationship with thrombin activity in vivo. Thromb Res 1991; 64:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/50\">",
"      Hofbauer LC, Spitzweg C, Heufelder AE. Graves' disease associated with the primary antiphospholipid syndrome. J Rheumatol 1996; 23:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/51\">",
"      Bowness P, Shotliff K, Middlemiss A, Myles AB. Prevalence of hypothyroidism in patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1991; 30:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/52\">",
"      Thomas RD, Croft DN. Thyrotoxicosis and giant-cell arteritis. Br Med J 1974; 2:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/53\">",
"      Kettaneh A, Prevot S, Biaggi A, et al. Hyperthyroidism in two patients with Crohn disease and Takayasu arteritis. Scand J Gastroenterol 2003; 38:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/54\">",
"      Duhaut P, Bornet H, Pin&egrave;de L, et al. Giant cell arteritis and thyroid dysfunction: multicentre case-control study. The Groupe de Recherche sur l'Art&eacute;rite&aacute; Cellules G&eacute;antes. BMJ 1999; 318:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/55\">",
"      Ratanakorn D, Vejjajiva A. Long-term follow-up of myasthenia gravis patients with hyperthyroidism. Acta Neurol Scand 2002; 106:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/56\">",
"      Weissel M, Mayr N, Zeitlhofer J. Clinical significance of autoimmune thyroid disease in myasthenia gravis. Exp Clin Endocrinol Diabetes 2000; 108:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/57\">",
"      Kiessling WR, Pflughaupt KW, Ricker K, et al. Thyroid function and circulating antithyroid antibodies in myasthenia gravis. Neurology 1981; 31:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/58\">",
"      Aarli JA, Thunold S, Heimann P. Thyroiditis in myasthenia gravis. Acta Neurol Scand 1978; 58:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/59\">",
"      Marin&oacute; M, Ricciardi R, Pinchera A, et al. Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab 1997; 82:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/60\">",
"      Marin&ograve; M, Barbesino G, Pinchera A, et al. Increased frequency of euthyroid ophthalmopathy in patients with Graves' disease associated with myasthenia gravis. Thyroid 2000; 10:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/61\">",
"      Sekiguchi Y, Hara Y, Takahashi M, Hirata Y. Reverse 'see-saw' relationship between Graves' disease and myasthenia gravis; clinical and immunological studies. J Med Dent Sci 2005; 52:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/62\">",
"      T&eacute;llez-Zenteno JF, Cardenas G, Esta&ntilde;ol B, et al. Associated conditions in myasthenia gravis: response to thymectomy. Eur J Neurol 2004; 11:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/63\">",
"      Hofmann WW, Denys EH. Effects of thyroid hormone at the neuromuscular junction. Am J Physiol 1972; 223:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/64\">",
"      SAHAY BM, BLENDIS LM, GREENE R. RELATION BETWEEN MYASTHENIA GRAVIS AND THYROID DISEASE. Br Med J 1965; 1:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/65\">",
"      HAVARD CW, CAMPBELL ED, ROSS HB, SPENCE AW. Electromyographic and histological findings in the muscles of patients with thyrotoxicosis. Q J Med 1963; 32:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/66\">",
"      Ramsay ID. Electromyography in thyrotoxicosis. Q J Med 1965; 34:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/67\">",
"      Olson BR, Klein I, Benner R, et al. Hyperthyroid myopathy and the response to treatment. Thyroid 1991; 1:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/68\">",
"      Horak HA, Pourmand R. Endocrine myopathies. Neurol Clin 2000; 18:203.",
"     </a>",
"    </li>",
"    <li>",
"     Kaminski, HJ. Ruff, RL. Endocrine myopathies (hyper- and hypofunction of adrenal, thyroid, pistuitary, and parathyroid glands and iatrogenic corticosteroid myopathy). In: Myology, 2nd ed, Enngel, AG, Franzini-Armstrong, C (Eds), McGraw-Hill, New York 1994. p.1726.",
"    </li>",
"    <li>",
"     Kissel, JT. Mendell, JR. The endocrine myopathies. In: Handbook of clinical neurology myopathies, Rowland, LP, Dimauro, S, (Eds), Elsevier Science, New York 1992. p.527.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/71\">",
"      Erkintalo M, Bendahan D, Matt&eacute;i JP, et al. Reduced metabolic efficiency of skeletal muscle energetics in hyperthyroid patients evidenced quantitatively by in vivo phosphorus-31 magnetic resonance spectroscopy. Metabolism 1998; 47:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/72\">",
"      Sinclair C, Gilchrist JM, Hennessey JV, Kandula M. Muscle carnitine in hypo- and hyperthyroidism. Muscle Nerve 2005; 32:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/73\">",
"      Lle&oacute; A, Sanahuja J, Serrano C, et al. Acute bulbar weakness: thyrotoxicosis or myasthenia gravis? Ann Neurol 1999; 46:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/74\">",
"      Lichtstein DM, Arteaga RB. Rhabdomyolysis associated with hyperthyroidism. Am J Med Sci 2006; 332:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/75\">",
"      Alshanti M, Eledrisi MS, Jones E. Rhabdomyolysis associated with hyperthyroidism. Am J Emerg Med 2001; 19:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/76\">",
"      Bennett WR, Huston DP. Rhabdomyolysis in thyroid storm. Am J Med 1984; 77:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/77\">",
"      Puvanendran K, Cheah JS, Naganathan N, Wong PK. Thyrotoxic myopathy: a clinical and quantitative analytic electromyographic study. J Neurol Sci 1979; 42:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/78\">",
"      Chiu WY, Yang CC, Huang IC, Huang TS. Dysphagia as a manifestation of thyrotoxicosis: report of three cases and literature review. Dysphagia 2004; 19:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/79\">",
"      McElvaney GN, Wilcox PG, Fairbarn MS, et al. Respiratory muscle weakness and dyspnea in thyrotoxic patients. Am Rev Respir Dis 1990; 141:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/80\">",
"      Verhagen WI, Schimsheimer RJ. Neurologic disease and thyrotoxic storm. A clinical and electrophysiological study. Electromyogr Clin Neurophysiol 1986; 26:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/81\">",
"      Hardiman O, Molloy F, Brett F, Farrell M. Inflammatory myopathy in thyrotoxicosis. Neurology 1997; 48:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/82\">",
"      N&oslash;rrelund H, Hove KY, Brems-Dalgaard E, et al. Muscle mass and function in thyrotoxic patients before and during medical treatment. Clin Endocrinol (Oxf) 1999; 51:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/83\">",
"      Klein I, Ojamaa K. Thyroid (neuro)myopathy. Lancet 2000; 356:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/84\">",
"      Fisher M, Mateer JE, Ullrich I, Gutrecht JA. Pyramidal tract deficits and polyneuropathy in hyperthyroidism, Combination clinically mimicking amyotrophic lateral sclerosis. Am J Med 1985; 78:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/85\">",
"      Feibel JH, Campa JF. Thyrotoxic neuropathy (Basedow's paraplegia). J Neurol Neurosurg Psychiatry 1976; 39:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/86\">",
"      S&ouml;zay S, G&ouml;k&ccedil;e-Kutsal Y, Celiker R, et al. Neuroelectrophysiological evaluation of untreated hyperthyroid patients. Thyroidology 1994; 6:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/87\">",
"      Pandit L, Shankar SK, Gayathri N, Pandit A. Acute thyrotoxic neuropathy--Basedow's paraplegia revisited. J Neurol Sci 1998; 155:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/88\">",
"      G&oacute;mez R, Shetty AK, Vargas A, et al. Chronic inflammatory demyelinating polyradiculoneurophathy and Graves' disease in an adolescent with Crohn's disease. J Pediatr Gastroenterol Nutr 1999; 29:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/89\">",
"      BRONSKY D, KAGANIEC GI, WALDSTEIN SS. AN ASSOCIATION BETWEEN THE GUILLAIN-BARR'E SYNDROME AND HYPERTHYROIDISM. Am J Med Sci 1964; 247:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/90\">",
"      Roquer J, Cano JF. Mononeuropathies in thyrotoxicosis. J Neurol Neurosurg Psychiatry 1992; 55:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/91\">",
"      Roquer J, Cano JF. Carpal tunnel syndrome and hyperthyroidism. A prospective study. Acta Neurol Scand 1993; 88:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/92\">",
"      Cakir M, Samanci N, Balci N, Balci MK. Musculoskeletal manifestations in patients with thyroid disease. Clin Endocrinol (Oxf) 2003; 59:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/93\">",
"      Rosati G, Govoni E, Aiello I, et al. Hyperthyroidism as a precipitating factor of amyotrophic lateral sclerosis: a case report. Acta Neurol (Napoli) 1980; 2:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/94\">",
"      RAVERA JJ, CERVINO JM, FERNANDEZ G, et al. Two cases of Graves' disease with signs of a pyramidal lesion. Improvement in neurologic signs during treatment with antithyroid drugs. J Clin Endocrinol Metab 1960; 20:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/95\">",
"      Garcia CA, Fleming RH. Reversible corticospinal tract disease due to hyperthyroidism. Arch Neurol 1977; 34:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/96\">",
"      Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998; 160 Suppl 1:S6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/97\">",
"      R&iacute;os A, Rodr&iacute;guez JM, Canteras M, et al. Surgical management of multinodular goiter with compression symptoms. Arch Surg 2005; 140:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30057/abstract/98\">",
"      Anders HJ. Compression syndromes caused by substernal goitres. Postgrad Med J 1998; 74:327.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4836 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30057=[""].join("\n");
var outline_f29_22_30057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COGNITIVE DYSFUNCTION AND SEIZURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MOVEMENT DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chorea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      STROKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cardiogenic embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PERIPHERAL NERVOUS SYSTEM MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Thyrotoxic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Graves' ophthalmopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4836\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4836|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/62/14316\" title=\"table 1\">",
"      Neuro complications of hyperthy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/24/35213\" title=\"table 2\">",
"      Criteria for thyroid storm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=related_link\">",
"      Moyamoya disease: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36585?source=related_link\">",
"      Neurologic manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=related_link\">",
"      Ocular myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=related_link\">",
"      Overview of tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=related_link\">",
"      Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=related_link\">",
"      Thyrotoxic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35239?source=related_link\">",
"      Treatment of Graves' orbitopathy (ophthalmopathy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=related_link\">",
"      Treatment of myasthenia gravis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_22_30058="HER2 and predicting response to therapy in breast cancer";
var content_f29_22_30058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HER2 and predicting response to therapy in breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/22/30058/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30058/contributors\">",
"     Hideko Yamauchi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30058/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/22/30058/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30058/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/22/30058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/22/30058/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/22/30058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Here we will review the relationship between expression of the biologic marker HER2 and response to endocrine therapy, chemotherapy, and HER2-directed therapies in the adjuvant setting and in women with advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE HER2 ONCOGENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HER2 oncogene encodes for a 185 KD transmembrane glycoprotein receptor with intracellular tyrosine kinase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/1\">",
"     1",
"    </a>",
"    ]. The HER2 receptor belongs to the epidermal growth factor receptor (EGFR) family of receptors, which are critical in the activation of subcellular signal transduction pathways controlling epithelial cell growth and differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] and possibly angiogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. HER2, the epidermal growth factor receptor 2, was previously called",
"    <span class=\"nowrap\">",
"     HER2/neu,",
"    </span>",
"    or ERBB-2. Amplification of HER2 or overexpression of its protein product is observed in 18 to 20 percent of human breast cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical utility of HER2 testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several guideline bodies, including the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), and the National Academy of Clinical Biochemistry, recommend routine testing of HER2 expression on newly diagnosed and metastatic breast cancers since 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. More recently, a joint committee representing ASCO and the College of American Pathologists (CAP) published guidelines that specifically address the technical and analytical aspects of HER2 testing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/12\">",
"     12",
"    </a>",
"    ]. This committee recommended strict accreditation for laboratories providing HER2 testing and periodic proficiency testing. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Recommendations of the ASCO/CAP consensus panel'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Knowledge of HER2 status impacts clinical care in several ways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Predictive value",
"    </span>",
"    &nbsp;&mdash;&nbsp;HER2 status predicts response to specific therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High levels of HER2 expression identify those women who benefit from treatment with agents that target HER2, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       lapatinib",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/13\">",
"       13",
"      </a>",
"      ]. Trastuzumab is remarkably effective both as monotherapy and in combination with cytotoxic chemotherapy in patients with HER2-positive metastatic disease. Furthermore, multiple randomized trials indicate a significant survival benefit when this drug is applied in the adjuvant setting for HER2-positive breast cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link\">",
"       \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The role of trastuzumab for HER2-negative breast cancers and those tumors displaying intratumoral heterogeneity is discussed below. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'HER2-negative patients'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      HER2 status appears to predict resistance or sensitivity to different types of chemotherapeutic agents, including anthracyclines and taxanes. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Response to chemotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      HER2 positivity may be associated with resistance to endocrine therapies. At least some data suggest that this effect may be specific to selective estrogen modulator (SERM) therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      ) and perhaps not to estrogen depletion therapies (eg, aromatase inhibitors), although the data are conflicting [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Response to endocrine therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Prognostic value",
"    </span>",
"    &nbsp;&mdash;&nbsp;HER2 overexpression is also associated with high rates of disease recurrence and death in the absence of adjuvant systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the value of this information in clinical practice is questionable. Guidelines from an ASCO expert panel recommend against using HER2 purely as a prognostic factor, although it strongly recommended its use as a predictive factor, as outlined above [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9\">",
"     9",
"    </a>",
"    ]. Given the substantial benefit of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for HER2-positive tumors, it is difficult to separate out the prognostic versus predictive utility of HER2.",
"   </p>",
"   <p>",
"    HER2 gene expression is an important component of the 21-gene recurrence score assay, which is recommended to assess the risk of recurrence in women with ER-positive node-negative early stage breast cancer who will be receiving adjuvant hormone therapy, to guide decisions regarding adjuvant chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ASSAYS FOR HER2 EXPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many ways to measure the activity of the HER2 oncogene; the best method, both in terms of the type of assay used and the optimal way to perform each type of assay, are controversial. The available assays are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HER2 gene amplification &mdash; Fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH), silver-enhanced in situ hybridization (SISH) or differential polymerase chain reaction (PCR)",
"     </li>",
"     <li>",
"      Overexpression of the HER2 protein product &mdash; Western blotting, enzyme-linked immunosorbent assay (ELISA), or immunohistochemistry (IHC)",
"     </li>",
"     <li>",
"      Overexpression of HER2 RNA &mdash; Northern blotting or reverse transcription PCR (RT-PCR)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    in metastatic disease enrolled patients after central testing using an IHC assay and the anti-HER2 antibodies 4D5 (the parent antibody of trastuzumab) and CB11 on formalin-fixed, paraffin-embedded tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Staining patterns were identified as negative (0 or 1+) or positive (2 or 3+), and only patients with 2 or 3+ staining were enrolled. Subsequent retrospective analyses have suggested that only patients with IHC 3+ staining benefited from trastuzumab [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/16-22\">",
"     16-22",
"    </a>",
"    ] and that only about one-fourth of IHC 2+ positive tumors had gene amplification when tested by FISH [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/7,23-26\">",
"     7,23-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, negative (0 to 1+) IHC was highly concordant with a lack of gene amplification by FISH; the false negative rate for IHC using Herceptest was 2 of 145 cases, or 1.4 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/24\">",
"     24",
"    </a>",
"    ] and between 4 and 7 percent in a second report [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/23\">",
"     23",
"    </a>",
"    ]. A preliminary report of a randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    versus paclitaxel alone in patients with IHC 0 to 1+ nonamplified HER2 failed to show a benefit from adding trastuzumab to paclitaxel in women with metastatic disease, but the study was underpowered and limited by the lack of central testing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most of the prospective randomized adjuvant trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , testing algorithms were somewhat arbitrarily developed consisting of either IHC testing and reflex FISH if IHC 2+, or reliance on FISH alone to detect gene amplification ratios of 2 or higher. Individuals with IHC 3+ or FISH positivity were considered suitable for enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. For the most part, these algorithms have been adopted into clinical practice, one of the reasons being that IHC is less expensive and more widely available than FISH.",
"   </p>",
"   <p>",
"    However, many of these assay methods have not been well standardized, particularly \"home brew assays\" that are set up in individual pathology laboratories using FDA-approved analyte-specific reagents [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/12\">",
"     12",
"    </a>",
"    ]. Prospective data obtained from two the adjuvant trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    indicate that at least 20 percent of the HER2 assays performed locally were incorrect when the same specimen was reevaluated in a high-volume central laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In contrast to the discordance between community and central laboratories, there is a high degree of agreement between central and reference laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/30\">",
"     30",
"    </a>",
"    ]. These data underscore the importance of using high-volume, experienced laboratories for HER2 testing to optimize the selection of patients most likely to benefit from trastuzumab.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recommendations of the ASCO/CAP consensus panel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal testing algorithm for assessing HER2 status in breast cancer as well as strategies to assure optimal performance, interpretation, and reporting of individual assays was addressed in a joint guideline from an expert panel of ASCO and the CAP, summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef75536 \" href=\"UTD.htm?6/56/7054\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommended algorithms for IHC and FISH testing of breast tumors are provided in the figures (",
"    <a class=\"graphic graphic_algorithm graphicRef64757 \" href=\"UTD.htm?10/5/10335\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef72767 \" href=\"UTD.htm?22/31/23039\">",
"     algorithm 2",
"    </a>",
"    ). In brief:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the prospective randomized trials used &ge;10 percent positive cells as a cutoff for a positive test, the",
"      <span class=\"nowrap\">",
"       ASCO/CAP",
"      </span>",
"      guideline recommended that a positive result be defined as uniform intense membrane staining of &gt;30 percent of invasive tumor cells in IHC in order to standardize readings [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/12\">",
"       12",
"      </a>",
"      ]. The percentage of patients who fall between 10 and 20 percent positive cells is very small (&lt;1 percent).",
"     </li>",
"     <li>",
"      Other criteria for a positive result is amplified HER2 gene copy number by FISH (average of more than six gene copies per nucleus for test systems without an internal control probe or an",
"      <span class=\"nowrap\">",
"       HER2/CEP",
"      </span>",
"      17 ratio of more than 2.2 where CEP is a centromeric probe for chromosome 17 on which HER2 resides).",
"     </li>",
"     <li>",
"      The panel recommended treatment with HER2-directed therapy according to the cutoffs used in the adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      trials (3+ by IHC, or FISH &ge;2.0 or IHC",
"      <span class=\"nowrap\">",
"       2+/FISH",
"      </span>",
"      &ge;2.0)",
"     </li>",
"     <li>",
"      A negative HER2 result is defined as either a IHC result of 1 or 1+ for cellular membrane protein expression (no staining or weak, incomplete membrane staining in any proportion of tumor cells), or a FISH result showing a",
"      <span class=\"nowrap\">",
"       HER2/CEP",
"      </span>",
"      17 ratio of less than 2.0 or an average of fewer than four copies of the HER2 gene per nucleus for systems without an internal control probe.",
"     </li>",
"     <li>",
"      Equivocal HER2 testing should trigger reflex HER2 testing using an alternative validated assay (IHC if FISH equivocal, FISH for an equivocal IHC). [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H275537479\">",
"    <span class=\"h2\">",
"     Intratumoral heterogeneity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of breast cancers may contain intratumoral heterogeneity in HER2 expression but not meet diagnostic criteria for HER2 overexpression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/32\">",
"     32",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     ASCO/CAP",
"    </span>",
"    panel defines heterogeneity as the presence of 5 to 50 percent HER2 amplification (FISH &gt;2.2) of cells tested [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/12\">",
"     12",
"    </a>",
"    ]. At this time the clinical significance of this finding is not clear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 6461 cases, heterogeneity (as defined by the",
"      <span class=\"nowrap\">",
"       ASCO/CAP",
"      </span>",
"      panel) was noted in 35 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/32\">",
"       32",
"      </a>",
"      ]. However, for tumors showing up to 30 percent amplified cells, there was no significant difference in recurrence free survival (RFS) compared to those without amplified clones. For those with 30 percent or more amplified clones, RFS progressively worsened as the proportion of amplified cells increased.",
"     </li>",
"     <li>",
"      In a second study 96 cases, intratumoral heterogeneity was identified in 11 percent and was an independent prognostic factor for disease free survival (hazard ratio [HR] 6.16, 95% CI 3.38-50.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether patients with tumors demonstrating HER2 intratumoral heterogeneity without meeting diagnostic criteria for HER2 overexpression should receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is not clear. Until more data become available, we suggest not administering trastuzumab in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HER2 discordance in metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of discordance in HER2 status in paired primary and metastatic breast cancers ranges between 2 and 25 percent, but averages about 10 percent (",
"    <a class=\"graphic graphic_table graphicRef62654 \" href=\"UTD.htm?36/57/37787\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. A substantial proportion of women with HER2-negative primary tumors acquired protein overexpression when their tumors recurred [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. In one, 10 of 61 initially negative tumors were HER2-positive at recurrence, prompting the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    in seven [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/40\">",
"     40",
"    </a>",
"    ]. HER2 status should be reanalyzed in biopsies obtained from newly recurrent metastases, particularly if the primary tumor was negative or only weakly positive.",
"   </p>",
"   <p>",
"    A potentially important new finding is that in some but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/22\">",
"     22",
"    </a>",
"    ], breast tumors that become resistant to endocrine therapy acquire HER2 expression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/39\">",
"     39",
"    </a>",
"    ]. The ramifications of this finding on the need to rebiopsy tumor tissue after a patient becomes refractory to endocrine therapy are poorly understood. This issue needs prospective study. The utility of HER2 in predicting response to endocrine therapy is discussed below. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Response to endocrine therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RESPONSE TO THERAPIES TARGETING HER2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the available HER2-directed agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    ), most data demonstrating HER2 as predictive of a response to treatment are based on studies of trastuzumab. These are discussed below. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Overexpression of HER2",
"    </span>",
"    &nbsp;&mdash;&nbsp;High levels of HER2 gene overexpression, as determined by either 3+ IHC staining or FISH positivity, are used to select patients for HER2-directed therapy, both in the adjuvant and metastatic disease settings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9,13\">",
"     9,13",
"    </a>",
"    ]. This practice is based upon retrospective subgroup analysis of early",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    trials in metastatic disease, which suggested that only patients with high levels of HER2 receptor overexpression (IHC 3+) or high copy number of the gene (&gt;2 by FISH) benefited from trastuzumab [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. It was subsequently recognized that about 24 percent of IHC 2+ positive tumors had gene amplification when tested by FISH [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/7,23-26,41\">",
"     7,23-26,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FISH is more expensive and less widely available than IHC. As recommended in guidelines issued by a joint",
"    <span class=\"nowrap\">",
"     ASCO/CAP",
"    </span>",
"    consensus panel, patients with IHC 2+ tumors should undergo confirmatory FISH testing prior to receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    (",
"    <a class=\"graphic graphic_algorithm graphicRef64757 \" href=\"UTD.htm?10/5/10335\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Assays for HER2 expression'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     HER2-negative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;While",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is thought to provide no benefit for patients with HER2-negative tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/42\">",
"     42",
"    </a>",
"    ], the possibility that some of these women might benefit has been raised [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/43-46\">",
"     43-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective, unplanned subgroup analysis of highly selected data from the adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    trials conducted by the US Intergroup and NSABP have produced speculation that at least some women whose tumors were HER2-negative on central testing benefited from the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preliminary data on central HER2 confirmatory testing from two trials testing the benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      also provide support for the concept that trastuzumab provides benefit for at least some HER2-negative women. In both trials, HER2 positivity by IHC or FISH was required for enrollment:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In NSABP B31, 10 percent of the 1662 tumor blocks tested by FISH and IHC were HER2-negative on central testing [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/47\">",
"       47",
"      </a>",
"      ]. In a preliminary report, relapse rates in this group were unexpectedly two- to threefold higher in the chemotherapy alone group compared to those who received chemotherapy plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      (21 versus 8 percent).",
"      <br/>",
"      <br/>",
"      In a later analysis, messenger RNA (mRNA) levels of HER2 in tumors that were centrally HER2-negative were significantly lower than those of HER2-positive tumors, providing strong evidence that the central HER2-negative tumors were indeed HER2-negative [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results were noted when 1783 tumor blocks from NCCTG trial N9831 were retested [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/48\">",
"       48",
"      </a>",
"      ]. In total, 103 appeared HER2-negative by both IHC and FISH. Relapse rates were twice as high in the doubly negative women who were treated with chemotherapy alone compared to those who also received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      , although the difference was not statistically significant (HR for DFS was 0.51, 95% CI 0.21 to 1.23).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional findings come from an analysis of data from CALGB 9840, in which women with metastatic disease thought to be HER2-negative (not IHC 3+ or FISH &ge;2.0) were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/27\">",
"       27",
"      </a>",
"      ]. The authors examined the tumor tissue blocks for polysomy of chromosome 17, the location of the HER2 gene, postulating that this finding might increase the copy number of HER2 below the threshold set for FISH positivity (ie, HER2 FISH ratios &lt;2.0) and be predictive of trastuzumab benefit.",
"      <br/>",
"      <br/>",
"      In data presented at the 2007 ASCO meeting, 25 of the 129 cases (19 percent) that were locally HER2 negative and centrally FISH negative had polysomy 17 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/43\">",
"       43",
"      </a>",
"      ]. When all 38 centrally tested FISH-negative cases with polysomy 17 were analyzed, response rates were significantly higher in those who received trastuzumab in addition to paclitaxel (63 versus 26 percent), although DFS and overall survival were similar.",
"      <br/>",
"      <br/>",
"      Chance alone could account for these observations, given the retrospective nature of the studies from which they were generated. However, there are also intriguing biologically plausible explanations as well. For example, neuregulin, a transmembrane growth factor that is frequently expressed in breast cancer, appears to modulate the clinical response to trastuzumab [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/46\">",
"       46",
"      </a>",
"      ]. In a small series of 11 patients with metastatic disease, neuregulin overexpression correlated with significantly longer event-free and overall survival in patients with low or normal HER2 expression who received trastuzumab but not in HER2 overexpressors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings require confirmation and further study. NSABP trial B47 is a randomized trial in which patients with HER2-low early breast cancer are assigned to adjuvant chemotherapy with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/49\">",
"     49",
"    </a>",
"    ]. Until more information is available, a change in standard practice (restricting trastuzumab use to patients with IHC 3+ or FISH+ tumors) is not warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16429464\">",
"    <span class=\"h2\">",
"     Trastuzumab resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all women with high levels of HER2 overexpression respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . Several potential mechanisms to explain trastuzumab resistance have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/50-56\">",
"     50-56",
"    </a>",
"    ]. These include downregulation of HER2 and alterations in or upregulated expression of genes involved in modifying biological pathways (eg, PTEN, insulin-like growth factor receptor I, and c-myc). One possibility is that a subgroup of HER2-positive tumors also expresses p95HER2, a truncated form of the HER2 receptor that has kinase activity but lacks the extracellular trastuzumab-binding domain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In a study of 46 patients with metastatic breast cancer, only one of nine patients expressing p95HER2 responded to trastuzumab, compared to 19 of 37 of those expressing full-length HER2 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preclinical data from this study also suggested that tumors expressing the truncated receptor remain sensitive to other therapies targeting HER2 (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    ). Although intriguing, until further information becomes available, analysis of tumors for any of these markers as a means of selecting patients for HER2-directed treatment is not warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Serum circulating ECD levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have addressed whether circulating HER2 protein ECD levels (c-ECD) predicts response to HER2-directed treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. Baseline c-ECD levels do not appear to predict for an increased odds of response, but in a pooled analysis of seven trials of first-line",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    with or without chemotherapy, patients with a 20 percent or greater decline in c-ECD levels over baseline had significantly higher response rates to trastuzumab (57 versus 28 percent) as well as significantly longer TTP and overall survival compared to those with a lesser degree of decline [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. However, a separate review of 63 studies concluded that concentrations of HER2 ECD are not consistently related to patient outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the clinical utility of assessing or following c-ECD levels during HER2-directed therapy is not established. The ASCO expert panel on tumor markers in breast cancer recommended against the use of serum c-ECD in any clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RESPONSE TO CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible link between HER2 overexpression and chemotherapeutic responsiveness was suggested by the observation of enhanced clinical activity with the addition of certain chemotherapeutic agents to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    in women with metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H111523989#H111523989\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'HER2-directed therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In vitro, drugs that target HER2 enhance the cytotoxic effect of several antineoplastics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. However, drug sensitivity assays that attempt to correlate HER2 overexpression with relative chemotherapy resistance have provided conflicting data [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. These disparate results can be explained by a number of factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The different mechanism of action of unrelated chemotherapy drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/72\">",
"       72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Variability of human breast cancer cell lines with regard to growth factor receptors, coamplification of other genes, and acquired drug resistance phenotypes",
"     </li>",
"     <li>",
"      Interaction between HER2 and a drug like",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      may not be direct but instead, receptor overexpression may simply be a marker or surrogate for a related coamplified gene, such as topoisomerase II, the true target gene for anthracycline sensitivity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anthracyclines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Adjuvant setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/73-79\">",
"     73-79",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/80\">",
"     80",
"    </a>",
"    ] studies report a correlation of HER2 positivity with better outcomes from adjuvant anthracycline-containing as compared to CMF-type (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ) chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. Two of the largest series are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Analysis of HER2 was performed in 992 women with node-positive disease who were randomly assigned to one of three dose levels of adjuvant CAF (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ) in a CALGB trial [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/73,84\">",
"       73,84",
"      </a>",
"      ]. The highest dose level of CAF was associated with significantly better disease-free survival (DFS) and overall survival, and the effect appeared confined to those women with overexpressed HER2.",
"     </li>",
"     <li>",
"      Formalin-fixed tumor specimens were obtained from 639 women with node-positive breast cancer enrolled on a National Cancer Institute of Canada trial comparing CEF (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ) versus CMF [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/79\">",
"       79",
"      </a>",
"      ]. For women with amplified HER2 tumors, CEF was significantly superior to CMF in terms of RFS (HR 0.52, 95% CI 0.34 to 0.80), and there was a trend toward better overall survival (HR 0.65, 95% CI 0.42 to 1.02, p = 0.06). CEF did not improve outcomes in women whose tumors did not overexpress HER2.",
"     </li>",
"     <li>",
"      A meta-analysis of eight trials comparing anthracycline versus non-anthracycline-based chemotherapy concluded that the benefits of adjuvant anthracycline use were confined to women with HER2-positive tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/85\">",
"       85",
"      </a>",
"      ]. For HER2-positive disease, anthracyclines were superior in terms of DFS (HR for relapse 0.71) and overall survival (pooled HR for death 0.73). In HER2-negative disease, anthracyclines did not improve either DFS or overall survival compared to combination chemotherapy regimens that did not contain an anthracycline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H760200091\">",
"    <span class=\"h4\">",
"     Topoisomerase 2-alpha (TOP2A)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing amounts of data support the view that HER2 overexpression simply represents a marker or surrogate for the real anthracycline target, the enzyme TOP2A, whose gene is adjacent to HER2 on chromosome 17q12-q21 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/86-96\">",
"     86-96",
"    </a>",
"    ]. Expression of the two genes is not necessarily linked; HER2 and TOP2A often have different copy numbers within the same tumor, and the two genes are not always",
"    <span class=\"nowrap\">",
"     coamplified/coexpressed",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. Adjuvant treatment of HER2-positive breast cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link&amp;anchor=H1352264107#H1352264107\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\", section on 'Non-anthracycline based therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2011 meta-analysis of five randomized trials comparing adjuvant anthracycline-containing treatment versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (CMF) assessed whether HER2 expression or TOP2A expression could predict response to anthracyclines [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/100\">",
"     100",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    was not administered to patients in any of the trials included in this analysis. Following adjustments for tumor size and number of positive nodes, treatment with anthracyclines resulted in the following improvements when compared with CMF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant improvement in both event-free survival (EFS) (HR 0.70, 95% CI 0.57-0.85) and overall survival (OS) (HR 0.73, 95% CI 0.59-0.90) in patients with HER2 overexpression.",
"     </li>",
"     <li>",
"      A significant improvement in EFS (HR 0.85, 95% CI 0.75-0.96) but not in OS (HR 0.87, 95% CI 0.75-1.01) in patients without HER2 gene amplification.",
"     </li>",
"     <li>",
"      A significant improvement in EFS (HR 0.60, 95% CI 0.47-0.77) and OS (HR 0.63, 95% CI 0.48-0.82) in patients with TOP2A alterations (deletion or amplification).",
"     </li>",
"     <li>",
"      A significant improvement in EFS (HR 0.86, 95% CI 0.76-0.98) but not in OS (HR 0.87, 95% 0.75-1.00) in patients with normal TOP2A levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results are confounded by the omission of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , which is now routinely used in the adjuvant setting for HER2-positive breast cancer patients. Although individual studies of an anthracycline-based regimen plus trastuzumab versus a non-anthracycline containing regimen plus trastuzumab have shown equivalent survival outcomes for HER2-positive patients, these data are controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/95,101\">",
"     95,101",
"    </a>",
"    ]. Many clinicians still believe anthracyclines provide additional benefits in combination with trastuzumab for patients with HER2-positive breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link&amp;anchor=H361579099#H361579099\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\", section on 'Choice of chemotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link&amp;anchor=H71308660#H71308660\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Choice of chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between HER2 positivity and response to anthracyclines in the setting of metastatic disease has been less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. However, as in the adjuvant setting, coexpression of TOPO2A may be the critical factor for anthracycline responsiveness rather than HER2 expression.",
"   </p>",
"   <p>",
"    This was shown in a study involving over 5000 patients with HER2-positive metastatic breast cancer who were treated with chemotherapy with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/95\">",
"     95",
"    </a>",
"    ]. TOP2A coamplification was associated with significantly improved survival when only anthracycline-containing chemotherapy was used for treatment, compared to outcomes in HER2-positive cancers lacking TOP2A coamplification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Taxanes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical investigations conducted on the influence of HER2 status on taxane responsiveness in women with locally advanced or metastatic breast cancer and in those receiving neoadjuvant or adjuvant therapy for operable disease have been small, often confounded by other concomitant therapies, and the results inconsistent and contradictory. The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 297 women with metastatic breast cancer who received either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      , women whose tumors were HER2-positive had a significantly longer progression-free survival and overall survival with a taxane-containing regimen, while there were no differences between the two regimens in those whose tumors were HER2-negative [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the adjuvant setting, the interaction between HER2 status and benefit from taxanes was evaluated in a subset of 1322 women who were treated on CALGB 9344 (which showed that four cycles of adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      after AC significantly improved disease-free survival and overall survival compared to four cycles of AC alone in women with node-positive breast cancer) and who had tissue blocks available for analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/107\">",
"       107",
"      </a>",
"      ]. In a prespecified analysis, there was a significant benefit from the addition of paclitaxel after AC in women with HER2-positive cancers, regardless of ER status, and in ER-negative tumors regardless of HER2 status, while there was no evidence of benefit in the subgroup with ER-positive, HER2-negative tumors. Other trials conducted in the adjuvant setting have failed to note an association between HER2 overexpression and benefit from taxanes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/108,109\">",
"       108,109",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link&amp;anchor=H1377341#H1377341\">",
"       \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Regimen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reports of preoperative (neoadjuvant) taxane therapy have come to disparate conclusions, with two suggesting a worse response rate [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/110,111\">",
"       110,111",
"      </a>",
"      ], and two others, no association between HER2 gene amplification or overexpression and response [",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/112,113\">",
"       112,113",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An ASCO expert panel on tumor markers in breast cancer recommended against the use of HER2 to guide the use of taxanes, at least in the adjuvant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Adjuvant setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the available data are far from conclusive, women whose tumors overexpress HER2 appear to derive greater benefit from anthracycline-based adjuvant therapy than from adjuvant therapy that is alkylating agent-based, such as CMF. The ASCO expert panel on tumor markers in breast cancer recommended that anthracycline-based adjuvant therapy be strongly considered in patients whose tumors had high levels of HER2 expression, as determined by 3+ immunohistochemistry or a FISH ratio &gt;2 by gene amplification, in the absence of a contraindication to use of this class of drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until further data become available, we preferentially recommend anthracycline-based therapy to patients with HER2-overexpressing breast cancer in the adjuvant setting, especially in patients with node-positive disease, unless such therapy is contraindicated (eg, in women with underlying heart disease, or women who received prior anthracycline therapy for a previous breast cancer). Whether adjuvant anthracyclines should be abandoned in patients with HER2-negative disease remains unsettled, and we do not withhold anthracyclines from these patients routinely. However, a non-anthracycline containing regimen (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ) is also acceptable.",
"   </p>",
"   <p>",
"    Whether HER2 overexpression should be used to select patients for taxane therapy remains uncertain. Although the data from CALGB 9344 suggest that the sequential use of four 21-day cycles of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    following AC provides little if any benefit for women with HER2-negative ER-positive tumors, these results require validation. Furthermore, it is not clear that the results can be extrapolated to regimens that contain dose-dense therapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    rather than paclitaxel. Given that most patients with HER2-positive disease will receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    with a taxane and anthracycline-containing chemotherapy regimen, the use of HER2-positivity to predict benefit from taxanes is a moot point. ASCO guidelines recommended against the use of HER2 to guide decisions about the use of adjuvant taxanes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link&amp;anchor=H1377341#H1377341\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no conclusive evidence to suggest that women with metastatic breast cancer whose tumors overexpress HER2 are likely to derive greater benefit from anthracycline-containing combinations as compared to CMF-like regimens. The data are insufficient at this time to draw clinically meaningful conclusions as to optimal treatment choice. The ASCO expert panel did not recommend that HER2 overexpression be used to make treatment decisions in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     RESPONSE TO ENDOCRINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amplification",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    overexpression of HER2 may be associated with primary resistance to endocrine therapy. Preclinical studies suggest physiologic \"cross-talk\" between the HER2 and ER signal transduction pathways. HER2 expression in human breast cancer cells is downregulated by estrogens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/114\">",
"     114",
"    </a>",
"    ]. Conversely, transfection and overexpression of HER2 in vitro promotes estrogen-independent growth and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    resistance in ER-positive (estrogen dependent) human breast cancer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/68,115,116\">",
"     68,115,116",
"    </a>",
"    ]. Among the hypothesized mechanisms whereby overexpression of HER2 renders cells hormonally independent are phosphorylation of the ER, ligand-independent ER activation, and regulation of hormone receptor expression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although these data provide a rational explanation for the lower response of HER2-overexpressing tumors to endocrine therapy seen in several clinical studies, most were retrospective and nonrandomized. Randomized trials have not provided consistent and confirmatory evidence of a lower response to endocrine therapy in HER2-overexpressing tumors, either in the adjuvant or metastatic disease setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although several trials have concluded that patients with HER2-overexpressing tumors are relatively resistant to adjuvant hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/118-123\">",
"     118-123",
"    </a>",
"    ], a similar number have failed to demonstrate such a relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/124-129\">",
"     124-129",
"    </a>",
"    ], and others even suggest a positive influence of HER2 overexpression on treatment response.",
"   </p>",
"   <p>",
"    It has been hypothesized that the adverse influence of HER2 overexpression is limited to therapies that are based upon a ligand binding agent (eg, selective estrogen receptor modulators [SERMs] such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ) as opposed to ligand-depleting therapy (eg, ovarian ablation, aromatase inhibitors). This hypothesis was based on an analysis of a trial in which 250 postmenopausal women with ER-positive breast cancer who were ineligible for breast conserving treatment were randomly assigned to four months of preoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    (2.5 mg daily) or tamoxifen (20 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/122\">",
"     122",
"    </a>",
"    ]. Women with HER2-positive tumors had significantly lower response rates to neoadjuvant tamoxifen when compared to those who were HER2-negative (17 versus 40 percent). In contrast, no difference was noted in the response to letrozole (69 versus 53 percent for HER2 positive and negative tumors, respectively).",
"    <br/>",
"    <br/>",
"    However, contradictory results have also been reported in two other trials conducted in the adjuvant setting (the ATAC and BIG 1-98 trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/130,131\">",
"     130,131",
"    </a>",
"    ]) as well as in women receiving endocrine therapy for metastatic disease. In both adjuvant trials, the benefits of an aromatase inhibitor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    or letrozole) over tamoxifen were seen regardless of HER2 status [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9,132\">",
"     9,132",
"    </a>",
"    ]. Furthermore, others have shown continued proliferation despite ongoing letrozole in close to 90 percent of HER2-positive tumors, suggesting that therapeutic resistance might become manifest later in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/133\">",
"     133",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Metastatic disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, although some studies suggest that HER2 overexpression is associated with relative resistance to adjuvant hormone therapy, particularly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , the data are conflicting. In particular, the available data are not considered sufficiently robust to use HER2 status as a factor in selecting an aromatase inhibitor over tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9,132\">",
"     9,132",
"    </a>",
"    ]. Guidelines from an expert panel on tumor markers in breast cancer convened by ASCO recommended that HER2 status not be used to withhold endocrine therapy for a patient with a hormone receptor-positive breast cancer, nor to select one specific type of endocrine therapy over another [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the adjuvant studies, trials examining the predictive value of HER2 status in women receiving hormone therapy for metastatic breast cancer have not compared treated versus untreated patients due to ethical concerns. Instead, multiple studies have assessed response rates to endocrine therapy among women with HER2-positive versus negative tumors. Although the results are mixed (",
"    <a class=\"graphic graphic_table graphicRef51788 \" href=\"UTD.htm?26/28/27084\">",
"     table 3",
"    </a>",
"    ), the bulk of evidence favors an adverse influence of HER2 overexpression on response to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/134-145\">",
"     134-145",
"    </a>",
"    ]. The following illustrates the range of findings in women with hormone receptor-positive tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Serum levels of circulating HER2 ECD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other researchers have studied the relationship between pretreatment serum levels of circulating HER2 ECD and response to hormone therapy in women with metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/136,137,144-149\">",
"     136,137,144-149",
"    </a>",
"    ]. Guidelines from an ASCO expert panel on tumor markers in breast cancer concluded that the measurement of circulating HER2 ECD was not recommended in any clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=see_link\">",
"       \"Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 18 to 20 percent of breast cancers have amplification",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      overexpression of the gene encoding the human epidermal growth factor receptor, HER2. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assay for HER2 is part of the diagnostic work-up on all breast cancers. The best method to select women for treatment is not clearly established. Guidelines for HER2 testing from a joint consensus panel of ASCO and the College of American Pathologists (CAP) are provided in the table (",
"      <a class=\"graphic graphic_table graphicRef75536 \" href=\"UTD.htm?6/56/7054\">",
"       table 1",
"      </a>",
"      ). &nbsp;(See",
"      <a class=\"local\" href=\"#H2\">",
"       'The HER2 oncogene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the substantial benefit of adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      for patients with HER2-overexpressing tumors, it is difficult to separate out the prognostic versus predictive utility of HER2. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical utility of HER2 testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with high levels of HER2 protein overexpression (immunohistochemical staining [IHC] 3+ or fluorescence in situ hybridization [FISH] &ge;2.0), we recommend administration of HER2-directed treatment in the adjuvant",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metastatic setting (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We recommend confirmatory FISH testing for patients whose tumors are 2+ by IHC (",
"      <a class=\"graphic graphic_algorithm graphicRef64757 \" href=\"UTD.htm?10/5/10335\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Assays for HER2 expression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with HER2-positive breast cancer, treatment should incorporate a HER2-directed agent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Response to therapies targeting HER2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the possibility of discordant HER2 expression from the primary and metastases, HER2 status should be reanalyzed in biopsies obtained from newly recurrent metastases, particularly if the primary tumor was negative or only weakly positive. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'HER2 discordance in metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend endocrine treatment for women with hormone receptor-positive, HER2-positive breast cancer in either the adjuvant or metastatic setting (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/22/30058/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Response to endocrine therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/1\">",
"      King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985; 229:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/2\">",
"      Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 1999; 96:4995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/3\">",
"      Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996; 15:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/4\">",
"      Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/5\">",
"      Giatromanolaki A, Koukourakis MI, Simopoulos C, et al. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin Cancer Res 2004; 10:7972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/6\">",
"      Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/7\">",
"      Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004; 291:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/8\">",
"      Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/9\">",
"      Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/11\">",
"      Sturgeon CM, Hoffman BR, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 2008; 54:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/12\">",
"      Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/13\">",
"      Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39.",
"     </a>",
"    </li>",
"    <li>",
"     Dowsett M, Allred, DC, et al. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial (abstract). Data presented at the 29th annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 17, 2006 (abstract 48). Abstracts available online at www.sabcs.org/SymposiumOnline/index.asp, accessed January 8, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/15\">",
"      Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/16\">",
"      Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/17\">",
"      Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/18\">",
"      Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/19\">",
"      Dressler LG, Berry DA, Broadwater G, et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005; 23:4287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/20\">",
"      Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005; 6:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/21\">",
"      Vogel CA, Cobleigh M, Tripathy D, et al. Superior outcomes with Herceptin (trastuzumab) in fluorescence in situ hybridization (FISH)-selected patients (abstract). Proc Am Soc Clin Oncol 2001; 20:22a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/22\">",
"      Brufsky A, Lembersky B, Schiffman K, et al. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 2005; 6:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/23\">",
"      Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005; 93:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/24\">",
"      Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19:2714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/25\">",
"      Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002; 77:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/26\">",
"      Lebeau A, Deimling D, Kaltz C, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001; 19:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/27\">",
"      Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: Phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC (abstract). Proc Am Soc Clin Oncol 2004; 23:6s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/28\">",
"      Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002; 94:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/29\">",
"      Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002; 94:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/30\">",
"      Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006; 24:3032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/31\">",
"      Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol 2011; 29:e458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/32\">",
"      Bartlett AI, Starcyznski J, Robson T, et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 2011; 136:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/33\">",
"      Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol 2012; 25:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/34\">",
"      Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/35\">",
"      Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005; 103:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/36\">",
"      Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/37\">",
"      Fabi A, Di Benedetto A, Metro G, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011; 17:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/38\">",
"      Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004; 101:9393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/39\">",
"      Lipton A, Leitzel K, Ali SM, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005; 104:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/40\">",
"      Guarneri V, Giovannelli S, Ficarra G, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/41\">",
"      Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004; 121:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/42\">",
"      Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26:1642.",
"     </a>",
"    </li>",
"    <li>",
"     Kaufman PA, Broadwater G, Lezon-Geyda K, et al. CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel with or without T in HER2+ and HER2- metastatic breast cancer (MBC) (abstsract). J Clin Oncol 2007; 25:34s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/44\">",
"      Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008; 358:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/45\">",
"      Tuma RS. Inconsistency of HER2 test raises questions. J Natl Cancer Inst 2007; 99:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/46\">",
"      de Alava E, Oca&ntilde;a A, Abad M, et al. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 2007; 25:2656.",
"     </a>",
"    </li>",
"    <li>",
"     Paik S, Kim C, Jeong J, et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31 (abstract). J Clin Oncol 2007; 25:5s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/48\">",
"      Perez EA, Reinholz MM, Hillman DW, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010; 28:4307.",
"     </a>",
"    </li>",
"    <li>",
"     Trial information available online at file://clinicaltrials.gov/ct2/show/NCT01275677?term=NSABP+B47&amp;rank=1 (Accessed on June 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/50\">",
"      Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/51\">",
"      Molina MA, S&aacute;ez R, Ramsey EE, et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 2002; 8:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/52\">",
"      Scaltriti M, Rojo F, Oca&ntilde;a A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/53\">",
"      Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/54\">",
"      Ritter CA, Perez-Torres M, Rinehart C, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13:4909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/55\">",
"      Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008; 68:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/56\">",
"      Belkhiri A, Dar AA, Peng DF, et al. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells. Clin Cancer Res 2008; 14:4564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/57\">",
"      K&ouml;stler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004; 10:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/58\">",
"      Esteva FJ, Cheli CD, Fritsche H, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005; 7:R436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/59\">",
"      Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005; 16:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/60\">",
"      Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 2008; 113:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/61\">",
"      Lennon S, Barton C, Banken L, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009; 27:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/62\">",
"      Leyland-Jones B, Smith BR. Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. Lancet Oncol 2011; 12:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/63\">",
"      Hancock MC, Langton BC, Chan T, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991; 51:4575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/64\">",
"      Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/65\">",
"      Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58:2825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/66\">",
"      Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/67\">",
"      Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000; 27:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/68\">",
"      Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992; 24:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/69\">",
"      Yu D, Liu B, Tan M, et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996; 13:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/70\">",
"      Pegram MD, Finn RS, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/71\">",
"      Orr MS, O'Connor PM, Kohn KW. Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells. J Natl Cancer Inst 2000; 92:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/72\">",
"      Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol 1999; 26:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/73\">",
"      Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/74\">",
"      Del Mastro L, Bruzzi P, Nicol&ograve; G, et al. HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br J Cancer 2005; 93:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/75\">",
"      Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/76\">",
"      Ravdin P, Green S, Albain K, et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone (abstract). Proc Am Soc Clin Oncol 1998; 17:97a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/77\">",
"      Albain K, Green S, Osborne K, et al. Tamoxifen versus cyclophosphamide, adriamycin, and 5FU plus either concurrent or sequential T in postmenopausal receptor positive, node positive breast cancer: A Southwest Oncology Group Phase III Intergroup Trial (abstract). Proc Am Soc Clin Oncol 1997; 16:128a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/78\">",
"      Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000; 92:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/79\">",
"      Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/80\">",
"      Zhang F, Yang Y, Smith T, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 2003; 97:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/81\">",
"      Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/82\">",
"      Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/83\">",
"      Miles DW, Harris WH, Gillett CE, et al. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 1999; 84:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/84\">",
"      Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/85\">",
"      Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/86\">",
"      Bartlett JM, Munro A, Cameron DA, et al. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 2008; 26:5027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/87\">",
"      J&auml;rvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/88\">",
"      Harris LN, Yang L, Liotcheva V, et al. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001; 7:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/89\">",
"      Knoop AS, Knudsen H, Balslev E, et al. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23:7483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/90\">",
"      Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/91\">",
"      Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/92\">",
"      Cardoso F, Durbecq V, Larsimont D, et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004; 24:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/93\">",
"      Arriola E, Rodriguez-Pinilla SM, Lambros MB, et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 2007; 106:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/94\">",
"      Scandinavian Breast Group Trial 9401, Tanner M, Isola J, et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/95\">",
"      Press MF, Sauter G, Buyse M, et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011; 29:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/96\">",
"      Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011; 29:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/97\">",
"      Bhargava R, Lal P, Chen B. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 2005; 123:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/98\">",
"      Jacobson KK, Morrison LE, Henderson BT, et al. Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer 2004; 40:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/99\">",
"      Glynn RW, Mahon S, Curran C, et al. TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer. Oncologist 2011; 16:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/100\">",
"      Di Leo A, Desmedt C, Bartlett JM, et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 2011; 12:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/101\">",
"      Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/102\">",
"      Hayes DF. Steady progress against HER2-positive breast cancer. N Engl J Med 2011; 365:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/103\">",
"      Revillion F, Hebbar M, Bonneterre J, Peyrat JP. Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients. Eur J Cancer 1996; 32A:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/104\">",
"      Niskanen E, Blomqvist C, Franssila K, et al. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 1997; 76:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/105\">",
"      Wright C, Cairns J, Cantwell BJ, et al. Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br J Cancer 1992; 65:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/106\">",
"      Konecny GE, Thomssen C, L&uuml;ck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004; 96:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/107\">",
"      Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/108\">",
"      Mart&iacute;n M, Rodr&iacute;guez-Lescure A, Ruiz A, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/109\">",
"      Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/110\">",
"      Formenti SC, Spicer D, Skinner K, et al. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 2002; 52:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/111\">",
"      Learn PA, Yeh IT, McNutt M, et al. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer 2005; 103:2252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/112\">",
"      Gonzalez-Angulo AM, Krishnamurthy S, Yamamura Y, et al. Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 2004; 101:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/113\">",
"      Pu RT, Schott AF, Sturtz DE, et al. Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis. Am J Surg Pathol 2005; 29:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/114\">",
"      Dati C, Antoniotti S, Taverna D, et al. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990; 5:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/115\">",
"      Liu Y, el-Ashry D, Chen D, et al. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 1995; 34:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/116\">",
"      Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/117\">",
"      Mueller H, Kueng W, Schoumacher F, et al. Selective regulation of steroid receptor expression in MCF-7 breast cancer cells by a novel member of the heregulin family. Biochem Biophys Res Commun 1995; 217:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/118\">",
"      Borg A, Baldetorp B, Fern&ouml; M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994; 81:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/119\">",
"      Sj&ouml;gren S, Ingan&auml;s M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/120\">",
"      Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/121\">",
"      De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003; 9:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/122\">",
"      Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19:3808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/123\">",
"      De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005; 11:4741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/124\">",
"      Knoop AS, Bentzen SM, Nielsen MM, et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001; 19:3376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/125\">",
"      Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000; 18:3471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/126\">",
"      Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/127\">",
"      Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/128\">",
"      St&aring;l O, Borg A, Fern&ouml; M, et al. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 2000; 11:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/129\">",
"      Love RR, Duc NB, Havighurst TC, et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003; 21:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/130\">",
"      Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008; 26:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/131\">",
"      Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008; 9:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/132\">",
"      Pritchard KI, Levine MN, Tu D. neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part II. J Clin Oncol 2003; 21:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/133\">",
"      Ellis MJ, Tao Y, Young O, et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006; 24:3019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/134\">",
"      Berns EM, Foekens JA, van Staveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995; 159:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/135\">",
"      Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/136\">",
"      Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/137\">",
"      Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/138\">",
"      Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998; 4:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/139\">",
"      Houston SJ, Plunkett TA, Barnes DM, et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999; 79:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/140\">",
"      Klijn JG, Berns EM, Bontenbal M, Foekens J. Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 1993; 19 Suppl B:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/141\">",
"      Fehm T, Maimonis P, Katalinic A, J&auml;ger WH. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 1998; 55:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/142\">",
"      Archer SG, Eliopoulos A, Spandidos D, et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995; 72:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/143\">",
"      Nicholson RI, McClelland RA, Finlay P, et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993; 29A:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/144\">",
"      Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003; 21:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/145\">",
"      Willsher PC, Beaver J, Pinder S, et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996; 40:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/146\">",
"      Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/147\">",
"      Hayes DF, Yamauchi H, Broadwater G, et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001; 7:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/148\">",
"      Colomer R, Llombart-Cussac A, Lloveras B, et al. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. Cancer 2007; 110:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/22/30058/abstract/149\">",
"      Hayes DF, Cirrincione C, Carney W, et al. Elevated circulating HER-2/neu related protein (NRP) is associated with poor survival in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 1993; 12:58a.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 780 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.150-9E46D5F071-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30058=[""].join("\n");
var outline_f29_22_30058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE HER2 ONCOGENE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical utility of HER2 testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Predictive value",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Prognostic value",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ASSAYS FOR HER2 EXPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Recommendations of the ASCO/CAP consensus panel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H275537479\">",
"      Intratumoral heterogeneity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HER2 discordance in metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RESPONSE TO THERAPIES TARGETING HER2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Overexpression of HER2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HER2-negative patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16429464\">",
"      Trastuzumab resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Serum circulating ECD levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RESPONSE TO CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anthracyclines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Adjuvant setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H760200091\">",
"      Topoisomerase 2-alpha (TOP2A)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Taxanes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Adjuvant setting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      RESPONSE TO ENDOCRINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Serum levels of circulating HER2 ECD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/780\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/780|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/5/10335\" title=\"algorithm 1\">",
"      Algorithm for IHC in assessment of HER2 status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/31/23039\" title=\"algorithm 2\">",
"      FISH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/780|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/56/7054\" title=\"table 1\">",
"      ASCO summary guideline recs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/57/37787\" title=\"table 2\">",
"      HER-2 overexpress primary mets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/28/27084\" title=\"table 3\">",
"      HER2 neu response to hormones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=related_link\">",
"      Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_22_30059="Risk classific exercise class A";
var content_f29_22_30059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk classification for exercise training: class A: apparently healthy individuals",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        This classification includes:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Children, adolescents, men &lt;45 years, and women &lt;55 years who have no symptoms or known presence of heart disease or major coronary risk factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Men &ge;45 years and women &ge;55 years who have no symptoms or known presence of heart disease and with &lt;2 major cardiovascular risk factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Men &ge;45 years and women &ge;55 years who have no symptoms or known presence of heart disease and with &ge;2 major cardiovascular risk factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Activity guidelines:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No restrictions other than basic guidelines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supervision required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        ECG and blood pressure monitoring:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not required",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * It is suggested that persons classified as Class A-2 and particularly Class A-3 undergo a medical examination and possibly a medically supervised exercise test before engaging in vigorous exercise.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694. Copyright &copy; 2001 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30059=[""].join("\n");
var outline_f29_22_30059=null;
var title_f29_22_30060="Geriatric depression scale";
var content_f29_22_30060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Yesavage geriatric depression scale (short form)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       1. Are you basically satisfied with your life?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Have you dropped many of your activities and interests?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Do you feel that your life is empty?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Do you often get bored?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Are you in good spirits most of the time?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Are you afraid that something bad is going to happen to you?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Do you feel happy most of the time?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Do you often feel helpless?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9. Do you prefer to stay at home, rather than going out and doing new things?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10. Do you feel you have more problems with memory than most?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11. Do you think it is wonderful to be alive now?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12. Do you feel pretty worthless the way you are now?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13. Do you feel full of energy?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       14. Do you feel that your situation is hopeless?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       15. Do you think that most people are better off than you are?",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\" colspan=\"3\">",
"       Score 1 point for each \"depressed\" answer (no on 1, 5, 7, 11, 13; yes on others)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       Normal",
"      </td>",
"      <td>",
"       3&plusmn;2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       Mildly depressed",
"      </td>",
"      <td>",
"       7&plusmn;3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       Very depressed",
"      </td>",
"      <td>",
"       12&plusmn;2",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Sheikh, JI, Yesavage, JA, Brooks, JO 3d, et al. Int Psychogeriatr 1991; 3:23.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30060=[""].join("\n");
var outline_f29_22_30060=null;
var title_f29_22_30061="Incomplete penetrance--pedigree";
var content_f29_22_30061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Example of a pedigree showing incomplete penetrance of a dominant trait",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 283px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incomplete penetrance. This pedigree illustrates incomplete penetrance for a dominant trait. Six of seven family members who harbor the mutation are affected, suggesting a penetrance of 0.857.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30061=[""].join("\n");
var outline_f29_22_30061=null;
var title_f29_22_30062="CAST beta blocker AA drugs";
var content_f29_22_30062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Beta blockers reduce mortality in high-risk patients after MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 299px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Cardiac Arrhythmia Suppression Trial (CAST) randomized 1735 postmyocardial infarction (MI) patients with a left ventricular ejection fraction &le;40 percent and ventricular arrhythmia to an antiarrhythmic drug (encainide, flecainide, or moricizine) or placebo. Patients who were receiving concomitant beta blocker therapy had a lower incidence of all-cause mortality, arrhythmic death, or cardiac arrest compared to those not receiving beta blockers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kennedy HL, Brooks MM, Barker AH, et al, for the CAST Invetigators, Am J Cardiol 1994; 74:674.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30062=[""].join("\n");
var outline_f29_22_30062=null;
var title_f29_22_30063="Stool sample 8";
var content_f29_22_30063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stool sample 8",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_22_30063=[""].join("\n");
var outline_f29_22_30063=null;
